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Abstract 
The lymph node (LN) microenvironment in Chronic Lymphocytic Leukaemia (CLL) is the 
main site of disease progression and maintenance.  Whilst isolated components of the LN 
niche have been studied in vitro, to date, no comprehensive architectural overview of the 
microenvironment has been attempted.  A more holistic view is essential in order to fully 
understand this disease.  LN CLL cells are likely to receive a complex array of survival 
signals from accessory cells which drive disease and protect against conventional 
therapeutics.  This study has embarked upon establishing reliable combinations of primary 
and secondary antibodies that permit multicolour immunohistochemical (IHC) interrogation 
of the CLL LN in formalin fixed paraffin embedded samples (FFPE). 
Analysis of cells in cell cycle using Ki-67 and morphological appraisal of tissues 
demonstrated a general lack of proliferation centre structures in the majority of CLL LN 
tissue samples.  Independent of disease stage, all tissues showed a significant presence of 
both CLL cells (PAX5+) and T cells (CD3+), often in close proximity to each other.  Whilst 
total numbers of T cells did not appear to relate to stage of disease, analysis of T-helper 
(CD4+) and T-cytotoxic (CD8+) subsets suggest a differential spatial distribution as disease 
progresses, in keeping with the understanding that the architecture of the CLL LN changes 
as disease progresses.  
To further investigate the impact of T cell -CLL cell interactions in the LN, an in vitro assay 
was developed to co-culture CLL cells with normal donor allogeneic CD4+ T cells.  A mutual 
protective effect in survival was observed in both the CLL and T cell populations.  However, 
despite increased 3H-thymidine incorporation being observed in co-cultures there was no 
evidence of induced proliferation in either T cell or CLL subsets.  Indeed the data suggest 
  
 
that 3H-thymidine incorporation observed upon co-culture of CLL cells with CD4+ T cells 
represents T cell supported CLL cell DNA repair.  If true, this scenario would have 
substantial impact upon the therapeutic options provided to patients in the future and 
warrants further investigation. 
The supportive role of monocyte-derived cells in CLL has been the focus of many in vitro 
studies in recent years, however very few studies have focused upon these cells in situ.  Here, 
CLL LN tissues were stained for the presence of macrophages (CD68+) and Nurse-like cells 
(CD163+).  The expression of CD68 was variable but the frequency of expression correlated 
with disease stage, where CD68+ cell frequency decreased as disease progressed.  CD163+ 
cells were detected in normal spleen, stage A, B & C CLL LN tissue, although the presence of 
these cells was highly variable between CLL LN samples, unrelated to disease stage.  These 
data highlight the complex role macrophage/monocyte cells may play in the CLL LN and 
the need for future studies to elucidate the impact of different subtypes of these cells. 
This work demonstrates that the architecture of the CLL LN microenvironment is complex, 
dynamic and heterogeneous and highlights the advantages multicolour IHC can present to 
the field for understanding the therapeutic opportunities in this disease. 
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1.1 B cells  
B cells in humans and other mammals form an integral part of the adaptive immune system 
and provide humoral immunity against invading pathogens (LeBien & Tedder 2008; LeBien 
2000; Raff 1973).  B cells are capable of raising specific immune responses against a vast array 
(~1013) different antigens (Ag) (Janeway et al. 2001; Reddy & Georgiou 2011).  B cells are also 
important antigen presenting cells (APC) which activate other cells in the immune system 
(LeBien & Tedder 2008; Pieper et al. 2013).  B cell immunity is highly important; in addition 
to poor immune responses against infections, many autoimmune diseases are caused by 
defects in B cell development, function or regulation (LeBien & Tedder 2008; Pieper et al. 
2013; Goodnow et al. 1990).  In addition, a large number of phenotypically distinct tumours 
may arise from B cells whose characteristics depend upon the stage of development of the 
initiating oncogenic B cell.  The B cell leukaemia Chronic Lymphocytic Leukaemia (CLL) is 
the focus of this project and the healthy development of B cells and their normal function 
will be initially discussed to provide context. 
1.1.1 B cell Development 
In adults, B cells (B lymphocytes) develop from common lymphocyte progenitor (CLP) cells 
within the bone marrow (BM).  Commitment to B lymphopoiesis is followed by CLP 
maturation into progenitor B cells (pro-B cell) and subsequently precursor B cells (pre-B cell).  
The ensuing development of functional and mature B cells depends upon the sequential 
rearrangement of several elements within the immunoglobulin (Ig) gene locus to encode a B 
cell receptor (BCR) which is then expressed on the B cell surface.  Until this point B cell 
development occurs without the engagement of antigen.  Once the putative BCR is expressed 
it becomes crucial for the cells survival as well as for the functional capacity of the resultant 
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mature B cell (LeBien & Tedder 2008).  Successive development of the B cell depends upon 
the cell’s experience of Ag. 
1.1.1.1 The BCR structure 
The BCR complex consists of a membrane bound antigen-specific immunoglobulin (Ig) 
flanked by two non-covalently associated proteins, Ig alpha (Igα) and Ig beta (Igβ) (CD79A 
and CD79B).  These proteins are necessary for the correct expression and function of the BCR 
(Minegishi et al. 1999; Ferrari et al. 2007).  The key functional element of the BCR complex is 
the antigen-binding Ig which, when bound by its cognate antigen, elicits B cell activation 
(Pieper et al. 2013).  The Ig is constructed from two heavy and two light chain proteins that 
are separately encoded.  The locus for heavy chains (IgH) is found on chromosome 14 
(14q32.33) and there are two loci that encode Ig light chains (IgL), which may be kappa (κ) or 
lambda (λ).  The λ light chain locus is on chromosome 22 (22q11.2) whilst the κ locus is found 
on chromosome 2 (2p11.2) (Lefranc 2014).  Both heavy and light chain proteins are encoded 
by gene sequences that have to be somatically recombined in each B cell prior to their 
expression.  The functional IgH and IgL both consist of a constant region encoded by the 
Constant (C) gene region and a variable region encoded by the combination of Variable (V), 
Joining (J) and Diversity (D) (IgH only) gene regions (figure 1).   
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Figure 1. B cell receptor structure. 
The B Cell Receptor (BCR) is comprised of 2 heavy and 2 light 
immunoglobulin chains (Ig), each with a constant and a variable region.   
Variable regions are encoded through combination of multiple gene loci;  
the heavy chain variable region by one each of Variable, Diversity and 
Joining regions, the light chain variable region by Variable and Joining 
regions only. The heavy chain constant region is encoded by Ig µ whilst 
the light chain constant region is encoded by κ or λ. These variable and 
constant regions are transcribed to produce a membrane bound IgM which 
in combination with Igα and Igβ form the  functional BCR.  The 
rearrangements of V,D and J gene regions generate diversity in the BCR 
antigenic repertoire. 
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1.1.1.2 Ig gene recombination 
The recombination of Ig genes is driven by the activity of the Recombination Activating 
Genes 1 and 2 (RAG1/RAG2) (Schatz et al. 1992; Oettinger et al. 1990) which are essential for 
the recombination process.  RAG1 and RAG2 are closely located to one another on 
chromosome 11p13 (Sherrington et al. 1992) and have little homology between the two 
sequences, although as a pair are highly conserved across many species.  RAG1 and RAG2 
are expressed exclusively in lymphoid lineage cells and their transduction into non 
lymphoid cells (such as fibroblasts) is sufficient to induce gene rearrangements (Schatz et al. 
1992).  The expression of RAG1 & RAG2 is downregulated in mature B cells which is thought 
to protect the cell from erroneous recombination of DNA as this may lead to translocations 
with oncogenic implications (Hiom et al. 1998). 
RAG1 and RAG2 induce double stand breaks in the DNA within the recombination signal 
sequence (RSS) to allow recombination of the V (D) J gene regions.  Production of the IgH 
chain of the BCR occurs first during development, with the RAG genes initiating a D to J 
gene rearrangement followed by a V to DJ gene rearrangement.  The initial constant (C) 
region of the IgH is mu (µ), however, during class switching later in development, another C 
region may be selected to replace µ.  Each of these C regions (µ, mu; δ, delta; ɣ, gamma; α, 
alpha; ε, epsilon) endows the functional Ig molecule with different capabilities.  Examples of 
these properties include that IgG (ɣ) has been shown to improve phagocytosis of antigens 
whilst IgE (ε) can induce the activation of mast cells and basophils initiating their 
degranulation, important in the response against helminths (Woof & Ken 2006; Wu & Zarrin 
2014; Nimmerjahn & Ravetch 2008).  Indeed, some C regions also contain sub-isotypes and 
these in turn have altered functional impact upon the antibody (Ab) produced by the B cell.  
This has been demonstrated by several groups, including observation of differential 
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responses seen from murine IgG1, IgG2α and IgG2β Ab against a capsular polysaccharide of 
Cryptococcus neoformans despite identical Ig variable regions (Torres et al. 2007).  In this way 
the same B cell may produce antibodies with different functional capacities whilst 
maintaining specificity by retention of the Ig V binding region. 
Following IgH chain transcription and translation, rearrangement of the V and J regions of 
the IgL variable region occurs, whilst either  κ or λ C genes are selected as the IgL C region.  
The combination of two IgH chains and two IgL chains form a putative BCR which is then 
expressed on the B cell surface. 
The expression of the master B cell regulator PAX5 is also important for the proper formation 
and expression of the BCR and development of B cells (Cobaleda et al. 2007).  PAX5 is a 
transcription factor with a large range of important roles necessary for B cell development 
including the recruitment of RAG1 and RAG2 to the human IgVH genes (Zhang et al. 2006; 
Fuxa et al. 2004). 
1.1.1.3 The Immature B cell 
With a BCR expressed on its cell surface, the B cell becomes an immature B cell and leaves 
the BM (figure 2).  At this stage immature B cells are already capable of responding to the 
presence of a subset of pathogens known as Type I Ags.  When activated in this manner the 
immature B cell clonally expands and differentiates into short lived plasma cells, which are 
capable of excreting non-membrane bound forms of the IgM they express as part of their 
BCR.  These secreted Ig are called antibodies (Ab) and can be raised independent of 
assistance from other immune cells.  Type I Ag that elicit these responses from immature B 
cells include common bacterial Ag such as lipopolysaccharides and free DNA (Kreig et al. 
1995). 
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1.1.2 B cell Maturation 
After the immature B cell migrates out of the BM, it circulates in the periphery until reaching 
secondary lymphoid tissues, such as a lymph node (LN) or lymphoid follicles within the 
spleen or gut-associated lymphoid tissues (GALT).  Upon entry into the LN the immature B 
cell becomes a mature naïve B cell which may be activated through the binding of a cognate 
Ag to its BCR.  This Ag may be free within the lymph inducing B cell differentiation into a 
short lived plasma cell, which secrete Ab.  Alternatively, the Ag may be presented to the 
naïve B cell via an antigen presenting cell (APC) such as a T helper cell (Th) or a follicular 
dendritic cell (FDC) leading to the formation of a germinal centre (GC) wherein the B cell 
will undergo rapid clonal expansion (figure 2) (LeBien & Tedder 2008; Pieper et al. 2013; 
Sagaert et al. 2007). 
1.1.3 B cell Activation 
The germinal centre in LN tissue is a region within which mature activated B cells proliferate 
profusely and undergo somatic hypermutation to create an amended BCR molecule with a 
greater affinity for the original antigen (Di Noia & Neuberger 2007).  This process allows a 
robust immune response and secures a specific long-term protection to the host against this 
antigen. 
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Figure 2. Healthy B cell development, maturation and activation . 
Diagrammatical representation of healthy B cell development, maturation 
and activation as described in Chapter 1.1  
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Engagement of the BCR by its cognate antigen causes activation of the B cell through the 
release of calcium (Ca2+) from intracellular stores.  Activation requires the crosslinking of 
multiple BCR complexes on the B cell surface, leading to the phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAM) found on the intracellular regions 
of the Igα and Igβ co-receptors.  This induces the recruitment and activation of several 
downstream signalling molecules such as SYK and LYN kinases which, once activated, cause 
phosphorylation and activation of Bruton’s tyrosine kinase (BTK).  In addition, 
phosphatidylinositol- 4,5-bisphosphate-3-kinase (PI3K) is activated, and together these lead 
to phospholipase C-gamma-2 (PLCɣ2) and phosphoinositol-diphosphate (PIP2) activation 
and eventual release of Ca2+, activating the B cell (Guo et al. 2000; Dubravka & Scott 2000; 
Kuwahara et al. 1996).  
1.1.4 Affinity Maturation 
Within the GC an activated B cell will undergo a process of affinity maturation which 
involves both Somatic Hypermutation (SHM) and class switch recombination (CSR) of the 
genes encoding the BCR.  Both of these processes fall under the control of the enzyme 
Activation Induced Deaminase (AID).  AID is responsible for the rearrangement and 
hypermutation of the BCR Ig variable gene structures (Muramatsu et al. 2000; Revy et al. 
2000).  AID facilitates the deamination of cytosine residues within the DNA of the Ig gene 
regions creating a uracil residue, which is then point mutated during the repair process. 
These point mutations lead to random variations within both the variable and constant 
regions of the Ig locus.  Mutations in the Ig variable region lead to the production of 
daughter B cells that express slightly different variable regions within the BCR molecules on 
the cell surface when compared to the parent cell (Di Noia et al. 2007; Di Noia & Neuberger 
2007).  These BCR molecules either possess a higher or lower affinity for the original 
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activating antigen and this process ultimately produces a daughter cell with a much higher 
affinity for the original antigen.  The daughter cells produced by SHM undergo selection for 
their ability to bind the original antigen via interaction with Th or FDC within the LN follicle.  
If a B cell is capable of strongly binding the Ag via its altered BCR it will progress to CSR and 
finally differentiation.  If a B cell fails to sufficiently bind the presented antigen it will 
undergo apoptosis.  Where AID induces mutation in the Ig C gene region, repair processes 
lead to the replacement of the chain with an α, δ, ɣ or ε chain instead in a process called CSR 
(Stavnezer 2008).   
1.1.5 Terminal Differentiation 
Following CSR, the high affinity mature B cell will proliferate and/or differentiate into one 
of two types of long lived high-affinity B cells; a memory B cell or a plasma cell (Pieper et al. 
2013).  Memory B cells reside within secondary lymphoid organs and will proliferate and 
terminally differentiate upon secondary expose to the same antigen to produce plasma cells 
(McHeyzer-Williams & McHeyzer-Williams 2005).  Plasma cells are non-replicating long 
lived cells which can secrete high-affinity antibodies.  These cells preferentially home to the 
BM microenvironment for stromal support necessary for long term survival (Underhill et al. 
2012).  
1.1.6 B cell tolerance and anergy 
During the process of B cell development some cells will generate BCR molecules that will 
react against self-Ag.  For a healthy immune system to develop, these self-reactive cells must 
be prevented from causing damage to the host.  In cases where this does not occur, 
autoimmune disease arises.  There are several mechanisms inbuilt within the immune 
system that protects the body against self-reactivity.  When newly developed BCR are 
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initially presented in the BM they undergo testing for self-reactivity.  Should a B cell be 
strongly self-reactive it will be destroyed and never enter the circulation (Goodnow et al. 
1991; Hartley et al. 1991), a phenomenon that was initially demonstrated in mouse models 
(Goodnow et al. 1988).  However, if a B cell has a low level of self-reactivity they may enter a 
state of anergy instead of being destroyed (Melamed & Nemazee 1997; Pieper et al. 2013).  
Within the periphery, should these anergic B cells bind a non-self-Ag with high affinity, they 
are brought out of their anergic state.  During affinity maturation, the cells undergo SHM 
and their BCR structure is mutated.  Those cells which lose self-reactivity and bind non-self-
Ag with high affinity will progress and survive.  This process of re-purposing self-reactive B 
cells provides a greater pool of B cells from which protection against infections can be raised 
(Heltemes-Harris et al. 2004).  In this way the body is able to balance the need for a large 
repertoire of antigenic binding receptor structures with the risk of autoimmunity.  However, 
the presence of anergic B cells provides the potential for their oncogenic transformation.  
Indeed it has been reported that some leukaemic cell types, including Chronic Lymphocytic 
Leukaemia cells (CLL), share many commonalities with anergic B cells such as low 
expression of IgM on the cell surface (Apollonio et al. 2013). 
As described above the development, maturation and activation of B cells is a complex and 
tightly regulated process within which there are inherent dangers to cellular integrity.  It is 
not surprising therefore that where elements of this machinery malfunction it can lead to 
tumorigenesis (Ramiro et al. 2006). 
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1.2 CLL Biology 
Chronic Lymphocytic Leukaemia (CLL) is a disease of mature B cells, which accumulate as 
CD5+ CD19+ cells in the bloodstream.  CLL usually affects older individuals, with a median 
age of 72 years at presentation (Oscier et al. 2012).  Following publication of the International 
Workshop in Chronic Lymphocytic Leukemia (iwCLL) 2008 guidelines, a diagnosis of CLL 
requires the detection of an absolute peripheral blood CD5+ CD19+ B cell count 
≥5x109cells/litre (Hallek et al. 2008).  Detection of a clonal population of B cells 
≤5x109cells/litre with a CLL phenotype is diagnosed as monoclonal B cell lymphocytosis 
(MBL).  During the course of their disease, approximately 5% of CLL patients will have a 
transformation of their disease into a high grade lymphoma called Richters Syndrome (RS). 
1.2.1 MBL 
MBL is divided into two categories based upon the quantity of monoclonal B cells in the 
blood; low grade MBL (≤0.5x109cells/L) and high grade MBL (≥0.5x109cells/L – 
≤5x109cells/L) also known as clinical MBL.  Whilst low grade MBL has a low risk for 
progression to CLL, approximately 1-2% of individuals with high grade MBL progress to 
stage A CLL classification per year (Strati & Shanafelt 2015).  The mechanisms for this 
progression are as yet poorly understood and it is currently unclear as to whether there are 
driver mutations present or whether the microenvironmental signals play a larger role in 
CLL disease initiation (Ghia et al. 2012).  The similar immunophenotypic markers and 
advancement of high grade MBL suggest that all cases of CLL have preceding clinical MBL 
but this requires confirmation.  Stratification of these individuals is needed in the future to 
assist in ensuring therapy is appropriately provided. 
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1.2.2 Richters Syndrome  
Between 5-10% of CLL patients have a transformation of their disease into a high grade B cell 
lymphoma, a process known as Richters Syndrome (RS).  The most common form of 
lymphoma arising in RS is diffuse large B cell lymphoma (DLBCL), although in rare cases the 
transformation may lead instead to Hodgkins lymphoma (Parikh & Shanafelt 2014).  RS may 
develop de novo or from a mutation within a sub-clone of the patient’s CLL disease causing 
its rapid outgrowth.  Prognosis for RS individuals is poor as disease is aggressive and often 
refractive to many therapies that have efficacy in CLL or DLBCL.  Indeed, whilst great 
advances have been made in the management and treatment of CLL, these have not 
transferred to RS patients.  The driving mutations leading to RS are as yet unconfirmed 
although it is reported that commonly mutated master genes such as MYC are affected.  As 
untreated CLL patients have also been shown to develop RS it appears there is an inherent 
risk of transformation within the disease, although RS risk may also be affected by prior 
therapy  (Chigrinova et al. 2014; Tsimberidou & Keating 2005).  The genomic profile of RS 
shows a level of complexity in mutational events that sits between CLL and de-novo DLBCL 
(relatively low - high respectively) (Chigrinova et al. 2014).  This indicates that RS is a related 
but distinct condition, likely with a need for its own distinct therapeutic strategies.  Whilst 
the outlook for these patients is poor with conventional therapy (OS approximately 5–8 
months after diagnosis) the use of new therapeutic combinations, such as Ibrutinib and 
Rituximab,  may hold significant promise for these patients (Tsang et al. 2015).   
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1.3 CLL Stratification 
The highly variable clinical course of individual CLL patients renders it important to stratify 
patients for their risk of progression and need for treatment.  The Rai or Binet classification 
systems (figure 3) are used to separate patients based on lymphocyte count and 
lymphadenopathy (enlarged lymph nodes).  In addition, molecular markers including the 
mutation status of the Ig variable heavy chain gene (IgVH) (Hamblin et al. 1999), CD38 
(Damle et al. 1999) and zeta chain activated phosphatase 70 (ZAP-70) cell surface expression 
levels (Wiestner et al. 2003) have also been shown to correlate strongly to patient prognosis.  
Individuals who have a high expression of CD38, ZAP-70 or have unmutated IgVH genes (U-
CLL) (i.e. CLL B cells have not undergone SHM) tend to have a more rapidly advancing 
disease course, are considered “high risk” and more likely to require intensive therapy. 
1.3.1 IgVH gene mutation status impacts survival  
It has been suggested due to the striking survival differences between mutated and non-
mutated IgVH gene diseases (M-CLL and U-CLL respectively) (figure 4) that CLL should be 
subdivided into two different diseases (Hamblin et al. 1999) and treated accordingly.  This 
observation also initially suggested that CLL may arise from two different cell types, albeit 
that both cell types would be CD5+ B cells from early development.  The exact cellular 
origins of CLL remain as yet unconfirmed however, with supporting data published for both 
single cellular origin and two cell origin theories.  Whilst survival differences between U-
CLL v.s. M-CLL are greatly different, GEP of CLL cells revealed that the overall expression 
profiles of these subtypes show only minor differences, supporting the theory of a single 
cellular origin (Klein et al. 2001; Rosenwald et al. 2001).  As such, the originating cell type 
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within this disease remains a controversial topic and different CLL subtypes have common 
features to memory B cells, naïve B cells and anergic B cells. 
1.3.2 Common genetic aberrations in CLL 
With the advent of new technologies, such as in-depth sequencing, there is now a plethora of 
information regarding genomic aberrations found in CLL.  Due to the heterogeneic nature of 
the disease, some mutations are rarely applicable to the general patient population; however 
there are several mutations, commonly found in CLL, which bear the potential to be targeted 
as a treatment strategy (Strefford 2014). 
1.3.2.1 13q deletion 
The most commonly occurring mutation in CLL is 13q deletion (del(13q)) (60-80%) which has 
been shown be a favourable marker of overall survival (OS) in CLL when found in isolation 
(Döhner et al. 2000).  Trisomy 12, another relatively common mutation (10-15%) has also 
been implicated in improved OS, although deaths within this patient cohort have also been 
typically linked to the development of a secondary tumour type or disease transformation to 
RS (Strati et al. 2015).  In contrast, deletions in 11q (del(11q)) and 17p (del(17p)) have a 
strongly negative correlation with patient OS and the mechanisms for these are relatively 
well understood.   
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Figure 3. Prognostic staging systems. 
Details for the Rai and Binet staging system criteria.  Table informati on 
collated from Rai 1975, Binet 1980 and Hallek et al 2008  
 
 
 
 
 
 
Stage Definition
Binet Staging System
A
Less than 3 enlarged lymphoid areas* 
Hb ≥10g/dL and platelets ≥100,000/mm3
B
3 or more enlarged lymphoid areas* 
Hb ≥10g/dL and platelets ≥100,000/mm3
C
Any number of enlarged lymphoid areas 
Hb <10g/dL and/or platelets <100,000/mm3
*(cervical, axillary, inguinal, spleen or liver each count as a single area)
Rai Staging System
0 Lymphocytosis only (BM and PB)
I Lymphocytosis with lymphadenopathy
II Lymphocytosis with splenomegaly and/or heptomegaly
III
Lymphocytosis with anemia 
(Hb <11g/dL)
IV
Lymphocytosis with thrombocytopenia 
(platelets <100,000/mm3)
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Figure 4 Overall survival curves from comparison of patients with 
unmutated (U-CLL) versus mutated (M-CLL) IgVH genes. 
Image  taken from (Hamblin et al. 1999).  
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1.3.2.2 11q deletion 
Del(11q) impacts many genes, including most notably the ataxia telangiectasia mutated 
(ATM) gene (Austen et al. 2007; Stankovic et al. 1999; Rose-Zerilli et al. 2014).  ATM has 
several roles including sensing double strand breaks in DNA and activating the DNA 
damage machinery.  As such, its loss has grave consequences for maintaining genomic 
integrity (Stankovic et al. 1999; Rose-Zerilli et al. 2014) and is a distinct marker of poor 
outcome in CLL patients, also occurring independently of del(11q).   
1.3.2.3 17p deletion 
Del(17p) affects the TP53 gene, encoding the tumour suppressor gene p53 (Döhner et al. 
2000).  Whilst patients who are previously untreated rarely present with this mutation, 
greater than 50% of refractory patients possess this mutation.  Outcome in these patients is 
only improved by therapy which has action independent of p53 i.e. non-chemotherapeutic 
agents such as monoclonal antibodies or small molecule therapies.  This finding was 
highlighted by the poor outcome of del(17p) patients when treated with FCR therapy (Zenz 
et al. 2010; Hallek et al. 2010; Tam et al. 2008).  More favourable outcomes have now been 
seen using new combinations of therapy and trials are ongoing to determine the optimal 
therapies for this subset of high risk CLL patients (Hillmen 2011; Stilgenbauer & Zenz 2010).   
1.3.2.4 Clonal evolution 
Due to the relatively low presence of del(17p) in initially presenting CLL patients compared 
to 50% of refractory patients, greater focus has been placed upon better understanding of the 
clonal evolution occurring in CLL patients over the course of disease.  Whilst all CLL 
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patients will have a dominant CLL clone, there are also likely to be small numbers of other 
clones, known as sub-clones, within these patients.  The presentation of del(17p) in many 
refractory patients reflects the fact that cells with this mutation are less susceptible to 
traditional therapies.  As such, sub-clones possessing the del(17p) mutation are likely to 
survive initial therapies that otherwise eradicate the major clone.  The del(17p) sub-clones in 
these patients then outgrow at later stages and form the major clone of the relapsed disease, 
ultimately making relapsed disease relatively more difficult to treat.  The process of clonal 
evolution has been shown to occur via branching and linear progression and may be 
significantly affected by therapy choices (Schuh et al. 2012; Landau et al. 2013; Landau et al. 
2014). 
1.3.2.5 Additional mutations 
Mutations in NOTCH1 and SF3B1 genes are also relatively common within CLL.  NOTCH1 
mutations in CLL induce the constitutive expression of a highly active and stable Notch 
protein (Rosati et al. 2009; Puente et al. 2011).  Through whole genome sequencing it has 
been shown that mutations in the NOTCH1 gene are present in approximately 10-20% of 
patients and Notch signalling improves the ability of CLL cells to survive and resist 
chemotherapy in vitro when cultured on BM derived mesenchymal cells (Kamdje et al. 2012).  
This subclass of patients show a relatively poor OS, with the importance of this mutation on 
survival reflected by the promising results from therapies targeting the NOTCH pathway 
and protein (Lopez-Guerra 2015). 
SF3B1 encodes the splicing factor 3b protein which has an important role in RNA splicing.  
Independent of ATM or TP53 gene mutation status, SF3B1 mutants have defects in the DNA 
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damage response pathway and typically harbour more DNA damage (Te Raa et al. 2014).  
Present in ~10-15% of CLL patients, sufferers in this cohort are considered high risk as they 
typically have shorter overall survival and a shorter time to first treatment (Sutton & 
Rosenquist 2015).  
In addition to the discovery of these common mutations that can assist in the stratification of 
patients, the presence of shortened telomeres can identify asymptomatic patients who are 
likely to progress (Lin 2014).  Furthermore, screening of patient samples for combinations of 
these aberrations is showing promise for future assistance in the stratification of patients 
(Cornet 2015). 
Overall these advances are leading to a better understanding of patient prognosis, providing 
a more accurate stratification of individuals for therapies.  Ultimately, a better understanding 
of these mutations in combination with disease biology will afford clinicians the best 
opportunity to provide personalised therapy that suits each patient. 
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1.4 Impact of antigen and the BCR in CLL 
CLL cells have active, and in some cases constitutively active, BCR signalling which 
correlates to prognosis and disease progression in CLL (Stevenson & Caligaris-Cappio 2004; 
Stevenson et al. 2011).  As in the normal immune response, activated BCR signalling primes 
the cell for proliferation and promotes survival.  
In other B cell lymphomas this survival advantage is gained through mutational events in 
the BCR itself; leading to tonic constitutive signalling without the need for Ag binding and 
canonical activation (Davis et al. 2010), but this is not the case in CLL.  
As the BCR structure itself is not mutated to induce constitutive activation in CLL, this 
supported the premise that the disease may be driven by Ag stimulation.  Whilst no global 
common Ag has been indicated in CLL, there have been several cases of “stereotyped” BCR 
signatures found across patient cohorts (Agathangelidis et al. 2012).  This refers to 
populations of CLL cells within separate patients possessing the same variable IgH sequence, 
specifically within the complementarity determining region of the receptor, indicating that 
these BCR will bind the same antigen (Messmer et al. 2004).  This discovery was the first 
indication that CLL disease is driven by Ag and whilst there are commonalities between 
unrelated patient groups, there is still a great heterogeneity in Ag to which these stereotyped 
BCRs are raised and they include both self- and non-self Ag.  As such, whilst there is an 
acknowledged role for BCR signalling in CLL, the initial cause of the increased signalling 
does not appear to be common across the disease, and because of this seems unlikely to be an 
initiating step in formation of CLL.   
A subset of CLL patients with aggressive disease, U-CLL, have polyreactive BCRs that 
recognise multiple Ag epitopes (Hwang et al. 2014).  In U-CLL BCRs are activated when 
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exposed to several different antigen epitopes, making these cells more likely to receive a pro-
stimulatory and subsequent pro-survival response than a B cell with a specific BCR.  This is 
likely due to the nature of their BCR, which has not undergone SHM and so does not possess 
a highly specific Ag epitope.  This quality is likely to contribute to the aggressive nature of 
U-CLL. 
The overall importance of BCR signalling in the proliferation and progression of CLL has 
been further displayed via the impact of trials of several new therapies targeting the BCR 
and its downstream signalling molecules as discussed below (Chapter 1.6) (Byrd et al. 2013; 
Maffei et al. 2015; Brown et al. 2014).  
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1.5 Microenvironments in CLL 
CLL is a disease of multiple contrasting microenvironments; the peripheral blood (PB), the 
bone marrow (BM) and the lymph node (LN) compartments.  Whilst CLL cells circulate 
through all these compartments, it is only the BM and LN that provide chemoprotection to 
tumour cells during drug treatment.  This is thought to be provided via interaction with non-
malignant accessory cells.  
1.5.1 The Lymph Node, Bone Marrow and Peripheral Blood in CLL 
CLL cells within the PB are in G0/G1 arrest in contrast to the cell cycle profile of CLL cells 
within the LN (Messmer et al. 2005; Rosenwald et al. 2001; Herishanu et al. 2011).  Despite 
their quiescent status, it should be noted that CLL cells in the PB are metabolically active 
(Koczula et al. 2015) and are primed to circulate between compartments.  PB cells can be 
categorised into those which have recently left the microenvironment and those which have 
been in the periphery for an extended time based upon their cell surface expression profile 
(Calissano et al. 2011).  PB cells with CD5HighCXCR4Low have just egressed from the 
microenvironment whilst those homing to the niche present with a CD5LowCXCR4High 
phenotype.  High expression of CXCR4 (in addition to CXCR5) allows these cells to home to 
and enter LN and BM microenvironments where they receive support (Chiorazzi et al. 2005).  
Cells which home to the LN and BM microenvironments subsequently return to the PB and 
re-circulate cyclically between these environments. 
Traditionally CLL LN tissues and to a lesser extent, BM, have been reported to contain areas 
of highly proliferative tumour cells known as proliferation centres or psuedofollicles 
(Schmid & Isaacson 1994; Bonato et al. 1998; Ponzoni et al. 2011).  These proliferation centres 
(PC) are thought to be the regions within the LN environment where CLL cells interact with 
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non-malignant supportive cell types and proliferate (Ciccone et al. 2012; Plander et al. 2009; 
Patten et al. 2008; Vandewoestyne et al. 2011). 
1.5.2 Cellular support in the LN 
A multitude of cells are thought to interact with CLL cells in both the LN and BM, and these 
accessory cells are either activated or suppressed to the benefit of tumour growth.  These 
cells include but are not limited to T cells, Natural Killer cells (NK cells), Nurse-like cells 
(NLC) and mesenchymal stromal cells (MSC).  The investigation of the role of these cell types 
to date has been guided by the normal interactions of healthy B cells as well as observations 
of in vitro work, particularly with co-culture and mouse experimental models of CLL, in 
addition to observations during routine histopathology and diagnosis of CLL. 
1.5.3 T cells 
Collectively T cells have multifunctional relationships with other host cells in both normal 
homeostasis (health) and disease.  They are able to nurture and promote APC induced 
immune responses, as well as destroy aberrant host cells when presented with the correct 
stimulatory signals.  However, CLL cells are effective at dampening the natural aggressive 
anti-tumour response of T cells and equally preserve, promote and manipulate the nurturing 
interactions T cells have with their normal B cell counterparts, thus promoting immune-
evasion, pro-survival and pro-proliferative environments for the tumour cells (Riches et al. 
2010).  Indeed, CLL cells stimulated with T cell derived markers such as CD3 and CD28 
became activated and immunosuppressive (Hock et al. 2014).  These alterations in T cell 
responses can be broken down into distinct categories of adaptation. 
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1.5.3.1 CD4+ vs. CD8+ cell balance 
In CLL there is a skewing of the regular balance of Th (CD4+) to Tcyt (CD8+) cells, with many 
more Tcyt cells present in the PB of patients (Nunes et al. 2012; Gonzalez-Rodriguez et al. 
2010).  Despite the large relative number of Tcyt cells in CLL the anti-tumour immune 
response of these cells is ineffective.  CLL Tcyt cells are ineffective at forming functional 
immune synapses (IS) with CLL cells, due to a disrupted cytoskeleton and ineffective 
packaging and release of cytolytic enzymes.  CLL cells have been shown to negatively affect 
actin polymerisation in Tcyt, which is necessary for cell membrane movements, via their 
expression of multiple inhibitory ligands such as CD200 and CD274 (PD-L1) (Ramsay et al. 
2012).  In addition, the polarised release of granzyme from Tcyt is important for its successful 
induction of target cell death (Riches et al. 2010; Ramsay et al. 2008).  Recent work has 
highlighted that these CLL-induced impediments are due to induction of a T cell exhaustion 
phenotype as discussed below.  
1.5.3.2 T cell exhaustion 
CLL patient T cells have been shown to express the markers of chronic activation and GEP 
has indicated a pseudo-exhaustion phenotype (Görgün et al. 2005; McClanahan et al. 2015).  
This is due to the dampened ability of these T cells to mount an immune response despite 
their continued expression of IFNɣ, TNFα and IL-2, all pro-stimulatory signals which are 
atypical secretions for exhausted cells.  This combination of factors simultaneously dampens 
the immune response against CLL whilst supporting the tumour survival and proliferation 
(Görgün et al. 2005; Davis & Ritchie 2014).  This effect is mediated by the expression of 
exhaustion-inducing ligands by CLL cells such as CD200, PD-L1, CD276 (B7-H3) and CD270 
and their knockdown improves IS formation (Ramsay et al. 2012).  It has been recently 
demonstrated that the expression of PD-1L on the surface of CLL cells is a large contributor 
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to the suppression and pseudo-exhaustion of T cells in CLL (Riches et al. 2013).  Indeed a 
clinical trial testing the efficacy of an anti-PD1 antibody is currently underway and 
preliminary data gathered from testing in the TCL-1 mouse model of CLL has shown 
promising efficacy in reversing the T cell deficiency (McClanahan et al. 2015).  In this way 
physiologically relevant mechanisms which are present to protect the host against damaging 
self-reactive responses are manipulated in CLL for the benefit of tumour immune evasion 
and progression. 
1.5.3.3 CD4+ T cell compartment  
In addition to its suppression of the CD8+ Tcyt compartment, CLL also significantly impacts 
the CD4+ Th cell compartment.  CD4+ T cells have a crucial role in the activation and 
suppression of immune responses through their own interaction and activation via APC cells 
in healthy individuals.  It has been shown that CLL cells are capable of recruiting CD4+ 
CD40L+ T cells via the secretion of chemokines such as CCL22 (Ghia et al. 2002) and 
subsequently suppressing their immune response through the induction of IL-10 secretion by 
T cells.  Whilst CLL CD4+ T cells provide pro-stimulatory signals such as CD40L, IL-4 and IL-
21 which promotes CLL cell survival and proliferation (Pascutti et al. 2013; Girbl et al. 2013), 
the secretion of TNF family member signals such as BAFF and APRIL by T cells and CLL 
cells themselves lead to the activation of several receptors including TACI (Haiat et al. 2006).  
Downstream signalling from TACI induces the secretion of the immunosuppressive cytokine 
IL-10 (Saulep-Easton et al. 2015), leading to a protective, pro-proliferative environment for 
CLL cells with dampened T cell immune responses.  
Whilst T cells are known to be heavily involved and impactful in CLL, full details of these 
processes have yet to be confirmed.  The presence and interaction between various T cell 
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subsets and CLL cells in the LN microenvironment need to be carefully studied to allow a 
better understanding to shape drug use in this disease. 
1.5.4 Natural Killer Cells 
NK cell responses are also heavily dampened in in CLL; they have ineffective IS formation, 
similar to the impact upon the CLL Tcyt cell compartment (Kay & Zarling 1987).  Recently 
further details into the mechanisms of suppression have been highlighted including 
secretion of inhibitory ligands by CLL cells (Reiners et al. 2013).  The suppressive effects of 
CLL cells upon NK cells has been shown to be reversible in vitro by addition of cytokines, or 
the use of the immunomodulatory drug Lenalidomide (Acebes-Huerta et al. 2014; Lagrue et 
al. 2015; Huergo-Zapico et al. 2014). 
1.5.5 Macrophages and Nurse-like cells 
Monocyte-macrophages lineage cells are the chameleons within the haematopoietic system, 
capable of developing in to a multitude of tissue-specific cell types such as Kupffer cells or 
Langerhans cells (Lewis & Pollard 2006; Ross & Auger 1993).  In CLL, it has been 
demonstrated through immunohistochemistry and co-culture experiments that a novel cell 
type of monocyte origin are present in the microenvironments which support the survival 
and progression of CLL cells.  These cells are known as Nurse-like cells (NLC) and develop 
in high-density in vitro cultures of CLL cells (greater than 1x107cells/mL) after 7-14 days 
(Burger et al. 2000).  These cells were initially identified by the long term culture of CLL 
peripheral mononuclear blood cells (PMBC) but have since been indicated as present in the 
CLL LN.  Prior to their identification within the LN, it was shown that these cells were likely 
to have a role in this important environment as GEP profiling of CLL cells in NLC co-
Chapter One – General Introduction 
28 
 
cultures displayed similarities to profiles seen from LN residing CLL cells (Burger et al. 
2009). 
In vitro studies have shown that, much like CD4+ T cells, CLL cells actively recruit monocytes 
to the microenvironment via expression of a variety of chemokines (CCL3, CCL4, CCL5, 
CXCL10, IL-10) and induce a phenotypic change of these cells into an immunosuppressive 
NLC subtype (Giannoni et al. 2014; Bhattacharya et al. 2011; Filip et al. 2013; Ysebaert & 
Fournié 2011).  Indeed the development of a NLC phenotype appears to be driven by the 
microenvironment and proximity to CLL cells, as healthy donor monocytes can be subverted 
to produce pseudo-NLC by co-culture with NLC (Bhattacharya et al. 2011; Ysebaert & 
Fournié 2011; Tsukada et al. 2002).   GEP profiling of NLC have shown their similarity to 
immunosuppressive M2 macrophages which are anti-inflammatory and dampen immune 
responses.  It has recently been indicated that this subversion of monocyte/macrophage cells 
to  the NLC/M2 phenotype may be driven by secretion of nicotinamide 
phosphoribosyltransferase (NAMPT) by CLL cells (Audrito et al. 2015).  In addition to 
immunosuppression, CLL cell survival is improved in vitro via co-culture with NLC.  This is 
thought to be due in part to the secretion of TNF family members BAFF and APRIL which 
up regulate BCR signalling and NFκB expression (Nishio et al. 2005).  NLC are also 
attributed a role in CLL cell homing to the LN microenvironment due to the secretion of the 
chemokines CXCL12 and CXCL13 (Burger & Kipps 2006).  CLL cells home towards these 
signals moving up the concentration gradient, due to their expression of the respective 
receptors CXCR4 and CXCR5 on their cell surface.  Targeting this cell type within CLL has 
shown promise in vitro as an emerging CLL therapy (Stamatopoulos et al. 2012). 
The concept of a monocyte derived macrophage-like cell providing support to tumour cells 
is not novel.  NLC have their equivalents in Lymphoma Associated Macrophages and 
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Tumour Associated Macrophages in solid tumours (Lewis & Pollard 2006).  The presence of 
these cells, in many cases, have been linked to poorer prognosis, shorter progression free 
survival (PFS) and a more aggressive disease course (Lewis & Pollard 2006; Colvin 2014; 
Qian & Pollard 2010; Farinha et al. 2005; Lissbrant et al. 2000).  
1.5.6 Mesenchymal Stromal cells 
MSCs are found in both the BM and LN microenvironment.  Under normal physiological 
conditions, MSCs are important in B cell development (BM) and for the structure and 
organisation of GCs (LN).  MSCs have been shown to attract and activate CLL cells, observed 
through studies of in vitro co-culture experiments.  The presence of BM-derived Stromal 
Cells (BMSC) in vitro has been shown to elicit protective and pro-survival effects upon CLL 
cells isolated from patient PB.  These effects were stimulated via a mixture of contact 
dependent and secreted support, during which the BMSC were also activated.  
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1.6 Therapy 
The scope of treatments available for patients with CLL has dramatically changed over the 
last decade bringing improvements in remission rates and overall survival (Jain et al. 2015).  
This is in large part due to the growing appreciation for the significance of the 
microenvironment in CLL disease relapse and protection from therapy.  Many groups have 
called for new therapies to be developed targeting multiple important interactions believed 
to reside in these environments, acknowledging that without microenvironmental impact, a 
curative treatment is unlikely to be found (Burger 2011; Fecteau & Kipps 2012; Hayden et al. 
2011; Hillmen 2011; Ponzoni et al. 2011).  In recent years there has been progress towards this 
end, with the advent of new therapies targeting the BCR.  Some of these are now in late stage 
clinical trials, including idelalisib (a PI3Kδ inhibitor) and Ibrutinib (a BTK inhibitor). 
1.6.1 Idelalisib 
Idelalisib is a selective phosphoinositol-3-kinase-delta (PI3Kδ) inhibitor.  PI3Kδ is involved 
in propagating downstream signalling from multiple crucial receptors in CLL, including the 
BCR and CD40, promoting survival and proliferation.  For the initial few weeks of treatment, 
patients show rapid LN shrinkage coupled with lymphocytosis (Hoellenriegel et al. 2011; 
Lannutti et al. 2011).  Testing in vitro has shown Idelalisib inhibits CLL cell chemotaxis by 
reducing the levels of CXCR12 and CXCR13 expression by BMSC and NLC; signals crucial 
for homing of CLL cells to the microenvironments.  Idelalisib has also been shown to reduce 
the levels of survival signals CLL cells receive from BCR signalling, as well as reducing pro-
survival stromal cell interactions (Hoellenriegel et al. 2011; Lannutti et al. 2011; Maffei et al. 
2015).  In this way, Idelalisib reduces the protective crosstalk and retention of CLL cells in the 
LN, causing blasts to enter the PB.  It is thought that this type of exclusion from the LN 
starves some of the blasts from the survival signals they require, causing the apoptosis of a 
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proportion of the circulating cells (Messmer et al. 2005; Chiorazzi et al. 2005; Damle et al. 
2011).  In addition, CCL3 and CCL4 signalling of CLL cells is reduced, which may reduce 
their ability to recruit protective T cells to the niche. 
1.6.2 Ibrutinib 
Ibrutinib is a Bruton’s Tyrosine Kinase (BTK) inhibitor (Byrd et al. 2013).  BTK is an 
important component of the BCR downstream signalling cascade and requires 
phosphorylation and binding of phosphatidylinositol-triphosphate (PIP3) to be activated 
(Byrd et al. 2013; Pieper et al. 2013).  Once active, BTK translocates to the plasma membrane 
and its signalling cascade ultimately leads to calcium mobilisation, NFκB and PLCɣ 
activation.  Ibrutinib binds irreversibly to BTK stabilising it in an inactive state and treatment 
shows rapid lymphocytosis of CLL cells, with a reduction in BCR signalling and NFκB 
activation in vivo (Herman et al. 2014).  Despite seeing an overall reduction in cell number, 
clinical studies show low rates of remission (2% in previously treated patients, 13% in 
treatment naïve patients (Hutchinson & Dyer 2014)).  
With both Ibrutinib and Idelalisib, cessation of treatment sees a rapid reversal of 
lymphocytosis and down-regulated signalling.  Consequently patients are likely to need 
lifelong treatment which may prove to be challenging.  Due to this, toxicity profiles, whilst 
relatively manageable in early treatment, may pose problems in the longer term (Hutchinson 
& Dyer 2014).  Resistance to therapy has already been reported in clinical trials (Hutchinson 
& Dyer 2014; Woyach & Johnson 2015) and the growing number of cases of primary and 
secondary resistance demand further investigation and careful consideration of follow-up 
therapy options.  In addition, cost of treatment is of major concern which may be a limiting 
factor (Shanafelt et al. 2015)  If these issues can be addressed, these targeted therapies hold 
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great promise for CLL patients over the long term.  The lymphocytosis effects induced by 
Idelalisib or Ibrutinib are likely to be best utilised in combination therapies with monoclonal 
antibodies (mAb). 
1.6.3 Traditional course of therapy 
Most patients (70-80%) are typically diagnosed with CLL following a routine blood test 
(Oscier et al. 2012) and as such tend to have early stage disease (e.g. Binet stage A).  
Following the iwCLL guidelines for treatment (Hallek et al. 2008) most individuals will be 
assigned to observation rather than therapy until their disease progresses.  This clinical 
strategy may be altered in the near future due to the ability to stratify patients for risk of 
progression and the advent of new therapies which hold lower toxicity profiles than 
traditional treatments.  An example of this is the CLL12 trial (Langerbeins et al. 2015) which 
compares Ibrutinib monotherapy to the traditional “watch and wait” approach.  High risk 
stage A patients are identified in this study using a combination of risk factors including sex, 
age and IgVH gene mutation status as well as cytogenetic features.  The results of this study 
are as yet unconfirmed, but may initiate a revolutionary way to treat subsets of CLL patients 
in the future. 
Once patients are showing signs of progressive disease and require treatment, the type of 
therapy that is offered will depend upon their individual circumstances, including the 
presence of any other comorbidities (figure  5).  As the average age for CLL patients at 
diagnosis is 72, the presence of several comorbidities at time of therapy is not uncommon 
(Oscier et al. 2012).  The identification of differential patient cohorts within CLL has proved 
invaluable in ensuring that individuals receive the most appropriate course of treatment for 
their disease.  As previously discussed, CLL is highly heterogeneous and patients are 
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stratified into risk groups before treatment decisions are made (Oscier et al. 2012; Hallek et 
al. 2008).  Routinely patients will be tested for the presence of TP53 mutations after diagnosis 
as this indicates a separate subgroup of typically high-risk patients who respond poorly to 
the traditional use of DNA-damaging therapies and so require alternative treatments 
(Stilgenbauer & Zenz 2010; Zenz et al. 2010). 
1.6.4 “High Risk” patients (TP53 mutations) 
Individuals with TP53 mutations are treated using combinations of non-DNA damage 
inducing therapies.  Traditionally this may have been Alemtuzumab (a mAb targeting CD52 
expression) or another mAb in combination with steroids (to boost the patient immune 
response) but recent studies have shown great efficacy in treating this high-risk category 
with the new class of BCR pathway targeting drugs Ibrutinib and Idelalisib alone or in 
combination with mAb therapy (Farooqui et al. 2015; Chavez et al. 2013; Byrd et al. 2013)). 
New guidelines for the clinical treatment of CLL are continually updated to ensure the levels 
of patient care advances with the understanding of available therapies and it is currently 
recommended that, if eligible, patients should consider entry into clinical trials for new drug 
combinations.  Where ineligible for these trials, the front line therapy offered to each patient 
is dependent upon their individual circumstances.  
1.6.5 “Fit” Patients 
For those patients considered fit enough to withstand the related toxicities, Fludarabine, 
Cyclophosphamide and Rituximab (FCR) therapy is first choice.  FCR combines two 
chemotherapies with an immunotherapy; the purine analogue Fludarabine, the alkylating 
agent Cyclophosphamide and the mAb Rituximab. 
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Figure 5. Representation of the current therapy options for CLL patients.  
Therapy options available to CLL patients in the UK, table adapted from 
the Interim statement from the BCSH CLL Guidelines Panel 2015 (Follows 
et al. 2015; Oscier et al. 2012) Key. FCR; Fludarabine +Cyclophosphamide 
+ Rituximab CLB; Chlorambucil, BR; Bendamustine + Rituximab, mAb; 
monoclonal Antibody therapy, Pt; Patient  
  
Chapter One – General Introduction 
35 
 
Fludarabine interferes with DNA replication and repair whilst Cyclophosphamide causes 
inter- and intra- DNA strand crosslinks.  Rituximab is a chimeric (human/mouse) 
monoclonal antibody which targets CD20, a cell surface marker found on all malignant and 
non-malignant B cells.  Rituximab induces antibody dependent cytotoxic cell killing (ADCC) 
by NK cells, complement driven cytotoxicity, or direct apoptosis of the target cell.  As a 
result Rituximab clears the body of both healthy B cells and CLL cells (James & Kipps 2011; 
Keating et al. 2005).  Although Rituximab effectively clears the peripheral tumour burden in 
CLL, allowing patients to enter remission, relapse appears inevitable in most if not all 
patients. 
Whilst being first choice for this patient group, FCR does present significant toxicities (for 
example therapy related pneumonia or neutropenia) and due to its immunosuppressive 
nature, leads to a higher risk of secondary complications such as infection (Riches et al., 
2012).  Nevertheless FCR replaced FC as the treatment of choice for these patients, achieving 
CR rates of 72% compared to 20-30% for FC alone (James and Kipps, 2011, Keating et al., 
2005, Hillmen, 2011, Masood et al., 2011).   
1.6.6 “Less Fit” Patients 
Less fit patients ineligible for FCR will typically be treated with an alternative alkylating 
agent, Chlorambucil (CLB) in combination with a mAb therapy such as obinutuzumab, 
ofatumumab or rituximab as these combinations have been shown to be more effective than 
CLB alone (Goede et al. 2015; Hillmen et al. 2015; Hillmen et al. 2014).  Obinutuzumab is a 
humanized anti-CD20 monoclonal antibody which has an engineered Fc region, improving 
its affinity to the FcɣRIII on effector cells, improving ADCC and phagocytosis in addition to 
direct non-apoptotic tumour cell death.  Obinutuzumab in combination with CLB has been 
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shown have superior levels of PFS compared to Rituximab (Goede, et al. 2015).  
Ofatumumab is also capable of improved ADCC compared to Rituximab  (Bologna et al. 
2012).  Individuals who are considered too fragile to undertake CLB with mAb may be 
offered a mAb monotherapy or even CLB monotherapy which can help manage the disease 
but achieves low CR rates and as such could be considered palliative care (figure 5). 
It is widely accepted that FCR is less efficient at targeting CLL cells within the LN or BM 
microenvironments and so successful therapy with these agents will leave behind a small 
reservoir of tumour cells from which relapse occurs (Bottcher et al. 2012).  This inevitable 
relapse of patients having achieved a CR following chemoimmunotherapy is powerful 
evidence that that the current definition of CR does not represent eradication of all CLL cells 
but rather a reduction in CLL cell numbers to very low levels.  The role of the 
microenvironment has therefore become a focus in CLL research, both to understand the 
biology of the disease and to develop targeted treatments to disrupt the supportive 
interactions within these niches. 
1.6.7 Alternative Therapies 
There are also alternative therapies available which focus upon rebalancing the immune 
system and target the microenvironment such as Lenalidomide.  Lenalidomide is an 
immunomodulatory agent which has been shown to have multiple effects upon non-CLL 
cells in patients in addition to recent reports of direct anti-proliferative action upon CLL cells 
themselves (Fecteau et al. 2014; Acebes-Huerta et al. 2014).  These effects can be broadly 
divided into improving natural anti-tumour immune responses, reducing supportive 
microenvironmental signals and reducing homing signals to the LN.  Improvements in anti-
tumour immune responses include reinstatement of Tcyt cells ability to form an effective 
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Immune Synapse (Ramsay et al. 2008) and in multiple myeloma has been shown to reduce 
the threshold for NK cell activation (Lagrue et al. 2015).  In addition, Lenalidomide has been 
shown to suppress the supportive effect NLC cells provide to CLL cells, with GEP profiling 
indicating a reversion of NLC to a more M1 like phenotype (Fiorcari et al. 2014) and a 
relatively lower expression of CXCR12 (Fiorcari et al. 2014; Schulz et al. 2013).  Showing 
efficacy in relapsed patients and those with del(17p), Lenalidomide provides an alternative 
therapy option for these high risk patient cohorts (Sylvan et al. 2012), although it has also 
been reported to induce significant adverse effects in CLL patients.  These include tumour 
lysis syndrome, which is induced following the lysis of high numbers of CLL cells in a 
relatively short timeframe, leading to a storm of cytokines and intracellular metabolites 
being released into the blood (Coiffier et al. 2008).  In addition, patients may experience a 
tumour flare reaction where the LN become inflamed and patients may experience fever 
(Badoux et al. 2011).  Lenalidomide therapy requires careful management to protect patients 
from these effects, nevertheless its use shows promise, as a single agent and in combination. 
It should be noted that until relatively recently effective treatments for CLL have been 
associated with significant toxicities that carry a particularly high risk to the older group of 
CLL patients and benefits seen in trials of younger patients do not transfer to the wider elder 
cohort (Eichhorst et al. 2013) who are frequently excluded from trials due to underlying 
comorbidities.  As such this cohort of patients require careful management (Lamanna 2012; 
Goede & Hallek 2015; Tadmor & Polliack 2012; Ysebaert et al. 2015) and these advances in 
targeting the microenvironment with new non-chemotoxic therapies, as discussed above, 
have shown important promise particularly in the treatment of relapsed and refractory 
disease in the elderly and P53 cohorts of patients. 
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1.7 Modelling CLL 
For the successful development of new therapies which target CLL cells in the 
microenvironment it is essential to be able to model CLL disease in vitro.  Traditional models 
have been typically based upon the understanding of CLL from PB and BM samples, and 
have led to a wide variety of disease models being developed and routinely used in studies.  
Ultimately, a robust representation of the protective LN and BM environments is likely to 
best help in the development of effective, low toxicity therapies in CLL.  It should be noted 
that whilst strides are made in the understanding of these disease niches in vitro utilising PB 
samples, these findings should be reconfirmed in situ wherever possible to ensure that a real-
world view of the LN is being created. 
1.7.1 In Vitro culture models 
The culture of CLL cells in vitro commonly uses supportive stromal cells in combination with 
cytokine support (Hamilton et al. 2012; Hayden et al. 2011).  These assay systems attempt to 
provide the CLL cells with specific signals thought or known to be required for survival and 
proliferation.  This is with the purpose of replicating the microenvironment in CLL where 
cells are actively proliferating and protected from apoptosis.  This allows screening of 
therapies aimed at targeting microenvironment residing CLL cells.  
1.7.1.1 BM stromal cells 
These systems investigate the important cellular and supernatant derived interactions found 
within the BM and these cultures have been reported to protect CLL cells during drug 
treatment.  Through these models much information has been derived regarding CLL cell 
homing to the BM and how they are supported within them (Panayiotidis et al. 1996; Brachtl 
et al. 2011; Purroy et al. 2014; Lagneaux et al. 1998; Plander et al. 2009). 
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1.7.1.2 NLC  
NLC cultures have been widely studied since their initial observation in CLL cultures 
(Burger et al. 2000; Tsukada et al. 2002; Burger et al. 2013; Filip, Ciseł & Wasik-Szczepanek 
2013; Nishio et al. 2005) and research has shown their capabilities in supporting CLL cell 
survival, protection from drug-induced apoptosis, induction to proliferate and secretion of 
chemokine homing signals for CLL cells and for T cells. 
1.7.1.3 CD40L stroma 
CD40L, IL4 and IL-21 all represent important T cell derived signals which have been shown 
to be particularly important in CLL cell survival and proliferation (Bhattacharya et al. 2014; 
Ferrer et al. 2014; Pascutti et al. 2013; Hayden et al. 2011; Ahearne et al. 2013).  Systems which 
provide these signals allow the culture of CLL cells in vitro without need for laborious 
purification of BMSC or NLC outgrowth prior to CLL cell co-culture.  The CD40L and IL-4 
system has been shown to induce GEP profiles in the CLL cells similar to those in LN 
residing cells, currently indicating this system as one of the best for drug screening to target 
protected LN residing CLL cells (Hayden, data unpublished). 
1.7.1.4 Autologous T cells 
Several labs have reported the use of artificially stimulated autologous T cells for the culture 
and study of CLL cells.  In many cases a combinations of CD3, CD28, IL-2 and other 
compounds are used to stimulate isolated autologous T cells from patient samples, which are 
then co-cultured with cognate CLL cells (Asslaber et al. 2012; Pascutti et al. 2013).  T cells in 
CLL are heavily deregulated and whilst these assays are informative, pre-stimulated T cells 
are unlikely to fully recapitulate the response of T cells within the CLL microenvironment. 
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1.7.1.5 Allogeneic T cells 
The use of healthy donor allogeneic T cells has been previously reported, whereby the APC 
capabilities of T cells have been considered and showed a reduced capability to form 
functional immune synapse with CLL cells (Ramsay et al. 2008; Ramsay et al. 2012).  
Additionally, the use of whole PBMC samples artificially stimulated with CD3 and CD28 
(Hock et al. 2014; Asslaber et al. 2012) have induced activation of CLL cells and their 
subsequent suppression of PMBC activation.  These models allow the consideration of the 
immunosuppressive effects that CLL cells have upon their microenvironment and 
particularly upon T cells.  
1.7.2 In Vivo Mouse Models 
Mouse models of CLL have proven difficult to develop, likely due to the complex nature of 
the microenvironment that supports the disease in situ, but there are now several models 
widely accepted as useful for the study of CLL and investigation of potential new drug 
treatments.   
1.7.2.1 Eµ TCL-1 mouse 
The Eµ TCL-1 mouse is one of the most widely used models of CLL, where the TCL-1 gene 
(T cell leukemia-1) is induced to express in both mature and immature B cells by being 
placed under the control of an IgVH promotor and Eµ enhancer.  In this model, TCL-1 
expression in B cells causes a CLL-like disease to develop in mice over time with 
accumulation of IgM+ CD5+ lymphocytes.  These cells are quiescent (G0/G1) and mice 
progress to develop lymphadenopathy (Bichi et al. 2002).  Engraftment of CLL cells in mouse 
models have been improved via addition of other cell types such as T cells (Bagnara et al. 
2011) highlighting the importance of microenvironmental interactions in the establishment 
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and maintenance of this disease.  The Eµ TCL-1 mouse model has also proved a useful tool 
for drug response predictions; when treated with fludarabine, murine disease mimics the 
patient reaction, where an initial response develops into resistance and relapse (Johnson et 
al. 2006).  
1.7.2.2 Alternative Mouse Models 
The development of mouse models has been difficult but informative for the CLL 
community; for example different pathogenic pathways have been highlighted by their 
relative importance in producing a CLL-like disease.  Whilst Eµ TCL-1 mice develop CLL-
like disease, models impacting the cell death regulator BCL-2 or APRIL (a pro-proliferative 
signalling TNF family member) show an increase in B cell count but do not develop 
malignancy (Planelles et al. 2004; Lascano et al. 2013; Katsumata et al. 1992).  In addition, 
utilisation of mouse models have highlighted that CLL patients’ HSC have a propensity to 
produce clonal B cell populations.  NOD/SCID/IL-2null mice transplanted with HSC from 
CLL patients proceeded to develop multiple monoclonal B cell populations, in a manner 
similar to MBL disease (Kikushige et al. 2011).  This work suggests that there may be a 
propensity to develop CLL disease from an early stage in B cell development. 
Despite these insights garnered from the use of mouse models, the cellular support within 
murine tissues is unlikely to fully recapitulate the human LN or BM microenvironments and 
as such, these models need to be used in conjunction with ongoing in situ observation of 
human tissues and in vitro modelling.  Only by using multiple approaches is it likely that a 
full understanding of this disease will come to fruition.  
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1.8 Dissecting the LN microenvironment 
Whilst the CLL LN microenvironment is thought to be of paramount importance to the 
survival and proliferation of the tumour cells, the direct study of such tissues has inherent 
difficulties. 
CLL LN tissue samples are no longer collected routinely as diagnosis is obtained through the 
flow cytometric analysis of patient PB.  As such, supplies of LN material are relatively scarce 
compared to potential access to patient blood samples.  The tissues that are available are 
typically archived samples from historic cases of CLL and as such are formalin fixed paraffin 
embedded samples (FFPE).  FFPE tissue presents its own inherent challenges for 
interrogation as whilst Immunohistochemisty (IHC) is routinely performed by 
histopathogists, these analyses are single colour one-dimensional studies of tissue sections.  
In order to build an insight into the presence, proximities and potential interactions of cell 
types in the LN, multicolour analysis would be a better method.  However, commercially 
available antibodies for IHC staining of FFPE tissue are typically unsuitable for multiplexing 
as they are raised in the same species (typically mouse) and as such are likely to cross react 
and induce false positive signalling. 
Despite these challenges the study presented here utilised multicolour immunofluorescent 
staining and confocal microscopy to interrogate archived FFPE CLL LN tissue samples from 
seven CLL patients with the aim of gaining novel insight into the cell types and signals 
present within this tissue.  Complimentary to this work, in vitro co-cultures of CLL PB cells 
with allogeneic T cells were investigated to consider the interactions of T cells and CLL cells 
within the microenvironment.   
 
Chapter One – General Introduction 
43 
 
Study Aims; 
Overall this study looked to confirm the presence of specific cell types and signals in the LN 
microenvironment and provide a deeper understanding of this important niche.  In order to 
carry this out the following specific aims are highlighted:  
 To identify commercially available antibodies which sufficiently allow the 
interrogation of FFPE CLL LN material; initially as single stains and subsequently as 
panels of up to three antibodies, to highlight the complexity of the disease and the 
untapped potential of such tissues.  These antibody panels will initially focus upon 
investigating T cell subtypes and distribution within the CLL LN before considering 
the balance of proliferation and apoptosis within this important microenvironment. 
 To use the data from initial above described studies in the CLL LN to establish a 
more informed in vitro assay utilising T and CLL cells, to allow further interrogation 
of their interactions.   
 To broaden current knowledge about CLL LN complexity by more fully investigating 
the presence and role of additional accessory cells to T cells, including but not limited 
to macrophages and Nurse-like cells which have not been widely studied in situ to 
date.  
Chapter Two – Materials and Methods 
44 
 
 
 
 
 
 
 
2 MATERIALS & METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Two – Materials and Methods 
45 
 
2.1 Patient and healthy donor blood samples 
Consented CLL patient blood samples were collected during routine appointments at the 
University Hospital Birmingham and Heartland Hospital West Midlands under an ethically 
approved study [Dr G. Pratt (10/H1206/58)].  All CLL patient MNC samples used had ≥75% 
CD19+ cell presence and a lymphocyte count ≥ 1x107cells/mL whole blood.  Healthy donor 
blood samples were collected from volunteers following the ethically approved protocol for 
this project (15/NE/0045).  All samples were handled individually and not pooled. 
 
2.2 Blood Sample Preparation 
All centrifugation steps were performed in a Falcon 6/300 centrifuge unless otherwise stated 
and were performed as follows. 
2.2.1 Mononuclear Cell Isolation  
Mononuclear cells (MNC) were isolated from whole blood samples through the use of 
density centrifugation media which allows the separation of different blood cell components 
into fractions based on their density.  Blood was diluted in a 1:1 ratio with wash media 
(RMPI1640 supplemented with 100µg/mL streptomycin and 100U/mL penicillin) and 
carefully layered onto 15mL density centrifugation media (Ficoll Paque Plus, GE Healthcare, 
Buckinghamshire UK) in a 50mL tube (BD Falcon, Oxford, UK).  Samples were centrifuged at 
395 x g, 40 min, room temp (rt), centrifuge braking system turned off, to separate the blood 
into fractions.  The upper fraction (plasma) was discarded and the MNC layer beneath 
carefully removed, diluted in 20mL wash media in a universal tube (Sterilin, Newport, UK) 
and centrifuged at 511 x g, 10 min, rt.  The remaining fractions from the whole blood 
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preparation were discarded.  The MNC layer underwent two further wash steps by diluting 
the cell pellet in 20mL wash media and centrifuging at 225 x g, 10 min, rt, to pellet the cells, 
then the wash media was removed and discarded. 
2.2.2 Maintaining CLL samples in culture 
Prepared MNC were counted and the suspension diluted to 5x106cells/mL in ITS+ media 
(RPMI1640 media (Gibco, Life Technologies, Paisley, UK) supplemented with 1% ITS+ 
Premix (Corning, Amsterdam, The Netherlands) 100µg/mL streptomycin and 100U/mL 
penicillin (Gibco)).  Cell suspensions were seeded into vented tissue culture flasks (Corning) 
and placed into a humidified incubator at 37oC, 5% CO2 until use. 
2.2.3 CLL Cell Purification 
Where stated in Chapter 3, CLL samples were purified in order to remove all non-B cells.  
CLL MNC samples were purified using one of two types of commercially available isolation 
kits; either cells were purified by negative isolation where all other cell types are removed 
from the suspension (B-CLL cell isolation kit, human, Miltenyi Biotech, Surrey, UK), or 
through positive isolation where CLL cells are selected via their cell surface expression of 
CD19 (Dynabeads® CD19+ Pan B cell isolation and DETACHaBEAD® CD19 kit, both 
Invitrogen, Life Technologies).  It should be noted that trials of different commercially 
available isolation kits highlighted that some B cell isolation kits are ineffective for CLL cell 
isolation.  This is due to the inclusion of CD43 in the antibody cocktail, which is not 
expressed on healthy B cells but is expressed on CLL cells, leading to the loss of CLL cells 
during the purification process.  As such, caution is recommended when selecting an 
isolation kit for use with CLL cells.  For this project, both positive and negative isolation kits 
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selected were used followed manufacturer’s instructions and these methods are described 
briefly below. 
Following isolation as described above (2.2.1) CLL MNC samples were counted to determine 
cell number and the cell suspension centrifuged at 300 x g, 10 min, rt.   
2.2.3.1 Negative Isolation 
The supernatant was aspirated and the cell pellet resuspended in 40µL MACS buffer (see 
Appendix I) per 107 total cells.  10µL Biotin-antibody cocktail (containing anti-human CD2 [T 
cells, NK cells], CD3 [T cells], CD4 [T cells, monocytes, macrophages, dendritic cells], CD14 
[macrophages], CD15 [neutrophils, monocytes], CD16 [NK cells], CD34 [megakaryocytes], 
CD56 [NK cells], CD61 [thrombocytes], CD235a (Glycophorin A) [erythrocytes] and FceRIa 
[mast cells and basophils], targeting non-CLL cells within the MNC, was added per 107 cells 
and incubated (4oC, 10 min).  Cells were subsequently washed by addition of 2mL MACS 
buffer and the cell suspension was centrifuged at 300 x g, 10 min, rt.  The supernatant was 
discarded and the pellet resuspended in 80µL buffer per 107 cells.  20µL anti-Biotin 
microbeads were added per 107 cells and the cell suspension-bead mix was incubated (4oC, 
15 min).  The cell suspension was then applied to a prepared “LS” MACS column to which 
the non-CLL cell-bead complexes adhered.  The untouched CLL cells within the eluent were 
collected in a fresh universal tube, counted and resuspended at 5x106 cells/mL in ITS+ media 
ready for use. 
2.2.3.2 Positive Isolation 
The supernatant was aspirated and the cell pellet resuspended to 2.5x107 cells/mL in MACS 
buffer within a 15mL tube (BD Falcon).  The CD19 Pan B Dynabeads, which bind to CD19 
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expressing CLL cells and B cells only, were mixed thoroughly and 25µL beads were added to 
the cell suspension per 2.5x107 cells.  The cell-bead mixture was incubated (4oC, 20 min) with 
gentle mixing to allow binding of the Dynabeads to the CLL cells.  The mixture was 
subsequently placed on a Dynamag-15™ magnet (2 min) and whilst still on the magnet, the 
supernatant containing the non-CD19+ cells was removed and discarded.  To wash the 
CD19+ cell-bead pellet, the tube was removed from the magnet and 1mL fresh MACS buffer 
added, gently mixed and the solution replaced on the magnet.  The supernatant was 
removed and discarded and this wash step was repeated.  After washing, the CD19+ cell-
bead pellet was resuspended in 250µL ITS+ media per 2.5x107 cells (from original cell count).  
10µL DETACHaBEAD® solution was added per 250µL cell-bead suspension to cleave the 
magnetic beads from the CD19+ cells.  This mixture was incubated (45 min, rt) with gentle 
mixing.  The suspension was placed onto the magnet (2 min) and the supernatant containing 
the cleaved CD19+ cells was collected into a fresh universal tube.  This cell suspension was 
counted, washed with 5mL fresh ITS+ media and centrifuged at 300 x g, 10 min, rt.  The cell 
pellet was resuspended in ITS+ media at 5x106 cells/mL ready for use as described below.   
2.2.4 CLL Sample Irradiation  
Where required, CLL samples were irradiated (10 min) using a sub-lethal dose of gamma 
rays (2.38 Greys/min) (Button et al. 1981; Finney et al. 1996) to prevent their proliferation 
when stimulated in vitro.  These irradiated CLL cells were used during co-culture assays 
with CD4+ T cells or alone as control as described in Chapter 3. 
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2.2.5 CD4+ T cell Purification 
CD4+ T cells were purified from healthy donor MNC samples by negative selection using a 
commercially available isolation kit (CD4+ T cell Isolation kit, human, Miltenyi Biotech) 
following manufacturer’s instructions.  Samples were only utilised in co-culture assays 
providing they had ≥95% purity by flow cytometry analysis following purification.  Briefly 
the supernatant from the MNC pellet was aspirated and the cell pellet resuspended in 40µL 
MACS buffer (see Appendix I) per 107 total cells.  10µL Biotin-antibody cocktail, targeting 
non-CD4+ cells within the MNC, was added per 107 cells and incubated (4oC, 5 min).  30µL 
buffer per 107 cells was added to the cell suspension-antibody mix followed by 20µL anti-
Biotin microbeads per 107 cells.  The suspension was gently mixed and incubated (4oC, 10 
min).  The suspension was then applied to a prepared “LS” MACS column to which the non-
CD4+ cell-bead complexes adhered.  The untouched CD4+ T cells within the eluent were 
collected in a fresh universal tube, counted and resuspended at 5x106 cells/mL in ITS+ media 
ready for use. 
2.2.6 CellTrace™ CFSE and CellTrace™ Far Red labelling of cell populations 
CellTrace™ Carboxyfluorescein succinimidyl ester (CFSE) and CellTrace™ Far Red labelling 
was employed to allow monitoring of cellular proliferation in assay using flow cytometry 
analysis.  These dyes can cross the cell plasma membrane and bind covalently within cells to 
free amines.  As cells divide, their fluorescence intensity reduces and this can be monitored 
over time as a marker of proliferation. 
The MNC, purified CLL cells or CD4+ T cells were counted following their isolation and cell 
suspensions were washed twice by addition of 10mL warm Dulbecco’s phosphate buffered 
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saline (DPBS) (GE Healthcare) and centrifuged at 511 x g, 10 min, rt.  Subsequently cells were 
resuspended in 1mL warm DPBS and incubated with either 5µL 1mM CellTrace™ CFSE or 
CellTrace™ Far Red label (both Life Technologies) per 1x107cells.  Cells were incubated in 
the dark (10 min, rt), with occasional swirling of the cell suspension to ensure even labelling.  
Excess CellTrace™ label was washed away by the addition of 20mL 10% media (RPMI1640 
supplemented with 5% foetal bovine serum (FBS) (Invitrogen) 100µg/mL streptomycin and 
100U/mL penicillin) and centrifuged at 511 x g, 10 min , rt.  This wash step was repeated and 
subsequently cells were resuspended in ITS+ media at 5x106 cells/mL. 
 
2.3 Stromal Cell Preparation 
2.3.1 Stromal Cell Initiation 
Stably transfected murine L-cells expressing CD40L (L-40) and control L-cells (L-cont) [both 
a gift from Professor Gordon, University of Birmingham] were initiated in 10mL warm 10% 
media and cultured to confluence.  Stromal cells were routinely tested each month to check 
for maintenance of CD40L expression by flow cytometry. 
2.3.2 Stromal Cell Maintenance 
To maintain cells in a proliferative state, confluent flasks were washed once, by removal of 
the 10% media within the flask and the addition of 10mL DPBS to rinse off any remaining 
FBS containing media from the cells (as this would impede the action of the subsequent 
dissociation step).  The DPBS was discarded and cells were incubated with 3mL trypsin 
EDTA (GE Healthcare) (5 min) at 37oC 5% CO2 to allow dissociation of the cell monolayer.  
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Complete dissociation of the monolayer was confirmed via microscopy, and subsequently 
7mL 10% media was added to each flask.  The cell suspension was gently mixed and 
centrifuged at 511 x g, 10 min, rt.  The supernatant was discarded, the pellet agitated and 
resuspended in 10mL fresh 10% media and used to seed up to five fresh flasks.   
2.3.3 Mitomycin C Treatment of stromal cells to prevent growth 
Confluent large flasks were treated with 0.02M Mitomycin C (Sigma-Aldrich, Dorset, UK) for 
3 hours to prevent cell proliferation.  Flasks were subsequently washed three times with 
DPBS and cells were harvested as previously described using trypsin EDTA.  Cell 
suspensions were frozen (see below) and stored at -80oC prior to use.  
2.3.4 Stromal Cell Stock Freezing 
Cell suspensions were centrifuged at 511 x g, 10 min, rt, the supernatant discarded and cells 
were resuspended to 1x107cells/mL in freezing media (90% FBS (Invitrogen) 10% DMSO 
(Sigma)) and wrapped in cotton wool to slow freezing.  1mL aliquots were initially frozen at 
-80oC overnight, with longer term storage in liquid nitrogen until required. 
2.3.5 Creation of stromal control plates for assay cultures 
Mitomycin C treated L-40 and L-cont were initially brought up from freeze by addition to 
20mL 10% media, counted, and then made up to a density of 1x105cells/mL in fresh 10% 
media.  Cells were seeded into 96 well plates at 1x104cells/well.  Plates were placed into a 
humidified incubator for a minimum of 24 hours at 37oC, 5% CO2 to allow stromal cell 
attachment prior to their use in co-culture experiments. 
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2.4 Co-culture assay 
CLL MNC (or purified CLL cells) and CD4+ T cells were each seeded into clean 96 well plates 
at  2.5x105 cells/well in a final volume of  200μL media per well.  As a control, CLL MNC (or 
purified CLL cells) were seeded onto Mitomycin C treated L-40 and L-cont stroma plates (as 
described above, Chapter 2.3.5) at 2.5x105 cells/well, in a final volume of 200μL media per 
well.  All conditions at each time point were set in triplicate.  Cells were cultured for 3-7 days 
at 37oC, 5% CO2.  Where stated, media was supplemented with recombinant human IL-21 
(eBiosciences, Hatfield, UK) and/or recombinant IL-4 (R&D) at 25ng/mL and 1ng/mL 
respectively.  
2.5 Co-culture analysis 
All flow cytometry analysis was performed on a FACS Calibur (BD Biosciences) which was 
calibrated for each analysis assay run for this project.  This involved manual compensation to 
create new settings for each fluorophore panel combination. 
2.5.1 3H-Thymidine incorporation analysis 
24 hours prior to readout, appropriate triplicate wells were pulsed using 20μci/mL 3H-
thymidine (GE Healthcare).  Following the incubation period, the wells were transferred into 
a fresh plate and frozen at -20oC overnight.  To analyse, plates were defrosted and harvested 
onto a glass fibre filter mat (Thermo Fischer Scientific, Loughborough, UK) using a Skatron 
cell harvester (Skatron Instruments) which uses vacuum pressure to transfer cells from plates 
to the filter mats.  Filter mats were air dried and subsequently analysed using a Beta-Plate 
Scintillation counter (Skatron Instruments). 
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2.5.2 Bromodeoxyuridine (BrdU) incorporation analysis 
During co-culture set up required triplicate wells were supplemented with BrdU-containing 
ITS+ media (200µM/well) for the course of the experiment.  At readout, triplicate wells from 
96 well assay plates were pooled and analysed for incorporation of BrdU by 
immunfluorescent staining of cell cytospins (below). 
2.5.2.1 Making Cytospins 
Triplicate wells from 96 well assay plates were pooled and 100µL of the homogenous cell 
suspension centrifuged onto slides using a Shandon CytoSpin III Cytocentrifuge at 28.23 x g, 
3 min, rt.  Cytospins were air dried before being fixed by immersion in ice cold acetone (10 
min).  Slides were allowed to air dry completely before commencing immunfluorescent 
staining. 
2.5.2.2 Immunofluorescent Staining of Cytospins 
All wash steps for cytospins staining refer to the immersion of slides in 1x Wash Buffer 
(Dako, Cambridgeshire, UK) twice (2 x 3 min) and all steps were performed at rt protected 
from light unless otherwise stated. 
Sample cytospins were immunofluorescently stained for the incorporation of BrdU.  The cell 
spots were encircled by a hydrophobic pen (Dako) to create a waterproof barrier around the 
cells.  Slides were washed and incubated with 50µL Reagent A (Fix and Perm®, Life 
Technologies) (15 min).  Slides were washed and incubated with 50µL Reagent B (Fix and 
Perm®, Life Technologies) (20 min) followed by washing and incubation with FcR blocking 
solution (Innovex Biosciences, Wako, Germany) (10 min).  To unmask the epitope for the 
Anti-BrdU antibody, slides were washed and incubated with 305.6µg/mL DNAse I solution 
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(Sigma-Aldrich) (1 hour, 37oC).  This was followed by washing and incubation with the 
primary antibody: Anti-BrdU-FITC (BD Biosciences, Oxford, UK) (30 min).  Slides were 
washed and then incubated with the secondary antibody: anti-fluorescein/Oregon green 
Goat IgG Alexa488 (Invitrogen) (30 min).  Finally, slides were washed and immersed in 
Hoescht solution (20µg/mL) (Invitrogen) (1 min), immersed in dH20 (1 min) and then 
mounted with a coverslip using ProLong® Gold Anti-fade reagent with DAPI (Life 
Technologies).  Slides were allowed to cure overnight before being viewed on a Nikon A1 
confocal microscope (BALM). 
2.5.3 CellTrace™ CFSE and CellTrace™ Far Red Analysis 
Triplicate wells were pooled and washed with 2mL DPBS, centrifuged at 511 x g, 5min, rt, 
the supernatant discarded and the pellets agitated.  200μL FACS Fix solution (see Appendix 
I) was added per sample and tubes were stored at 4oC until analysed by flow cytometry 
(within one week). 
2.5.4 Cell Cycle Analysis 
Triplicate wells from 96 well assay plates were pooled and washed with 2mL DPBS, 
centrifuged at 511 x g, 5 min, rt the supernatant discarded and pellets agitated.  500μL cell 
cycle buffer (see Appendix I) was added per sample tube and tubes were stored at 4oC for 24 
hours before being analysed by flow cytometry. 
2.5.5 Analysis of Immunophenotype  
Samples were stained for the presence of several extracellular markers to check the 
immunophenotype of the cells within samples (see table 1 for full details).  Triplicate wells 
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from 96 well assay plates were pooled and stained using 2µL of each required antibody or 
relevant isotype control (BD Biosciences) per sample.  Samples were incubated in the dark 
(15 min, RT), and then washed with 3mL DPBS, centrifuged at 511 x g, 5 min, rt and the 
supernatant discarded.  Cell pellets were agitated, resuspended in 200μL FACS Fix and 
stored at 4oC until analysis by flow cytometry (within one week). 
 
Antibody Fluorophore Manufacturer 
Anti-CD3 FITC BD Biosciences 
Anti-CD4 PeCy7 BD Biosciences 
Anti CD19 APC BD Biosciences 
Table 1. Antibodies used for routine immunophenotyping of CLL 
samples by flow cytometry. 
 
2.5.6 Analysis of cell viability  
Samples were analysed for their viability using an AnnexinV/ Propidium Iodide flow 
cytometry assay.  Propidium iodide (PI) is commonly used as a converse marker of viability; 
healthy cells take up PI but simultaneously re-export PI via efflux pumps.  In contrast, dying 
cells lose membrane integrity and this allows PI to enter the cell and intercalate irreversibly 
with DNA.  Once intercalated, PI fluoresces and can be detected by flow cytometry.  
Triplicate wells from 96 well assay plates were pooled and washed with 3mL DPBS, 
centrifuged at 511 x g, 5 min, rt) and the supernatant discarded.  Cell pellets were agitated 
and resuspended in 200μL 1 x AV binding buffer with 5μL AnnexinV-FITC (BD Biosciences) 
and/or 5μL Propidium Iodide (BD Biosciences).  Samples were incubated (15 min, rt) and 
subsequently analysed by flow cytometry (within 1 hour). 
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2.6 CLL patient lymph node and healthy donor spleen Formalin Fixed Paraffin 
Embedded tissue samples 
Healthy donor spleen tissue samples and CLL patient lymph node tissue samples were 
accessed via the Human Biomaterials Resource Centre (HBRC) at the University of 
Birmingham under ethical approval for the centre and this project (09/H1010/75 and 
15/NE/0045 respectively). 
 
2.7 Staining of FFPE tissue samples 
2.7.1 Dewaxing and Antigen Retrieval 
Paraffin embedded tissue sections on glass slides were baked (30-60 min, 60oC) in a drying 
oven prior to processing, to ensure sections were well adhered to the slides.  Tissue sections 
were dewaxed and antigen retrieved using the commercially available citrate buffers and the 
automated Dako PT Link Module (Dako).  Whilst the tissue sections were baked, the 
retrieval buffers were warmed to 84oC within the PT Link Module.  Either pH6 (EnVision™ 
Flex Target Retrieval Solution, low pH, Dako) or pH9 (EnVision™ Flex Target Retrieval 
Solution, high pH, Dako) buffers were used for antigen retrieval.  Sections were immersed in 
the buffers and the buffers heated to 97oC and held at this temperature for 17 min (high pH) 
or 20 min (low pH) before being cooled to 65oC.  Tissue sections were subsequently allowed 
to rest in the cooled buffers (5 min) before being transferred to wash buffer (EnVision™ Flex 
Wash Buffer, Dako) to cool (5 min).   
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2.7.2 Chromogenic Staining 
All wash steps for chromogenic staining refer to the immersion of slides in 1x Wash Buffer 
(Dako) twice (2 x 3 min) and all steps were performed at rt protected from light unless 
otherwise stated. 
Sections were blotted to remove excess wash buffer and a hydrophobic pen was used to 
encircle the tissue to form a waterproof barrier.  Sections were incubated with 150µL of Fc 
Receptor block (Innovex Biosciences) (10min), washed and incubated with the relevant 
primary antibody (30 min) (see table 2 for a list of primary antibodies).  Sections were 
washed and then incubated with a horseradish peroxidase-conjugated (HRP) secondary 
antibody (Dako) (30 min).  Chromogenic developer solution was prepared by a diluting 20µL 
Diaminobenzidine substrate (Dako REALTM DAB+ Chromogen, (x50) (Dako)) in 1mL Dako 
REALTM Substrate Buffer (Dako).  Sections were washed and incubated with chromogenic 
developer solution (1-10 min) to allow staining to develop.  Once a sufficient depth of stain 
had developed sections were briefly rinsed in DPBS.  Sections were counterstained with 
haematoxylin (EnvisionTM FLEX Hematoxylin (Link), Dako) and subsequently dehydrated 
using increasing concentrations of alcohol solution: sections were immersed twice in fresh 
50% ethanol solution (5 sec), twice in fresh 70% ethanol solution (5 sec) and incubated in 96% 
ethanol (3 min).  Sections were then incubated in fresh 96% ethanol solution (2 min), 98% 
ethanol solution (2 min) and 100% ethanol (2 min) before being allowed to air dry 
completely.  Once dry, sections were mounted using dibutyl phthalate xylene (DepeX 
Mountant, Sigma-Aldrich).  Sections were viewed on an Olympus BX40 microscope once the 
mountant had fully cured (approx. 12 hours). 
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2.7.3 Haematoxylin and Eosin Staining 
All steps for haematoxylin and eosin staining (H&E staining) were performed at rt. 
Sections were blotted to remove excess wash buffer and a hydrophobic pen was used to 
encircle the tissue to form a waterproof barrier.  Sections were immersed in haematoxylin 
stain (Pioneer Research Chemicals Ltd, Essex, UK) (2 min) and subsequently rinsed under 
cold running tap water (2 mins).  Sections were subsequently immersed in 1% Acid Alcohol 
solution (Pioneer Research Chemicals Ltd) (30 sec) followed by immersion in Scott’s tap 
water substitute (Pioneer Research Chemicals Ltd) (2 mins).  Sections were counterstained by 
immersion in Eosin stain (Pioneer Research Chemicals Ltd) (2min) and subsequently rinsed 
under cold running tap water (2mins).   Sections were dehydrated by immersion in fresh 96% 
ethanol (1 min) followed by immersion in 100% ethanol (1 min) before being allowed to air 
dry completely.  Once dry, sections were mounted using dibutyl phthalate xylene (DepeX 
Mountant, Sigma-Aldrich).  Sections were viewed and images collected on a Zeiss AxioScan 
microscope (MISBU) once the mountant had fully cured (approx. 12 hours). 
2.7.4 Immunofluorescent Staining 
All wash steps for immunofluorescent staining refer to the immersion of slides in 1x Wash 
Buffer (Dako) twice (2 x 3 min) and all steps were performed at rt protected from light unless 
otherwise stated. 
Sections were blotted to remove excess wash buffer and a hydrophobic pen was used to 
encircle the tissue to form a waterproof barrier.  Sections were blocked by incubation with 
60µg/mL Donkey Serum (Jackson ImmunoResearch, Suffolk, UK) (10 min).  Sections were 
washed and incubated with the relevant primary antibody (30 min) (see table 2 for a list of 
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primary antibodies).  Sections were washed and incubated with the appropriate 
fluorochrome-conjugated secondary antibody (30 min) (see table 2 for a list of secondary 
antibodies used).  To achieve multicolour immunofluorescent staining and reduce cross-
reactivity of antibodies, when more than one epitope was being targeted on the same section, 
each epitope would be stained for separately.  In these cases, after the first primary antibody 
and secondary antibody staining steps had been completed, sections were washed and 
incubated again with Donkey Serum (10min) as a blocking step to reduce cross reactivity.  
The staining process was repeated as described above for each epitope.  Once all targets had 
been stained for, sections were washed and counterstained for nuclei using 20µg/mL 
Hoechst 3334 (1 min).  Finally, sections were mounted using ProLong Gold ™ Anti-fade 
mountant and cured overnight in the dark.  Sections were stored long term at 4oC protected 
from light until viewed on a Zeiss Zen 780 Confocal Microscope (MISBU) (within 14 days). 
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Primary Antibodies 
 
Mouse Antibodies 
Target Catalogue Number Manufacturer Dilution 
CD3 M7254 Dako 1:100 
Ki-67 M7240 Dako 1:50 
CD163 NCL-CD163-S Novocastra 1:200 
CD4 M731029-2 Dako 1:10 
CD68 M0814 Dako 1:150 
NAMPT AG-20A-0034-C100 Adipogen 1:200 
 Goat Antibodies 
Target Catalogue Number Manufacturer Dilution 
Pax5 AF3487 R&D Systems 1:20 
CD3 sc1128 Santa Cruz 1:10 
 Rabbit Antibodies 
Target Catalogue Number Manufacturer Dilution 
Ki-67 HPA000451 Atlas Antibodies 1:100 
CD68 HPA048982 Atlas Antibodies 1:200 
CD8a HPA037756 Atlas Antibodies 1:10 
CD3 IS503 Dako neat (prediluted) 
Cleaved Caspase 3 9661S Cell Signaling 1:300 
 Isotype Controls 
Target Catalogue Number Manufacturer 
 
Mouse IgG 10R-I169A-FIT Fitzgerald 
 
Rabbit IgG AB-105-C R&D Systems 
 
Goat IgG AB-108-C R&D Systems 
 
 
Secondary Antibodies 
 Target Catalogue Number Manufacturer Dilution 
Anti-Mouse Alexa488 715-545-151-JIR Jackson Immunoresearch 1:100 
Anti-Rabbit Alexa647 711-605-152-JIR Jackson Immunoresearch 1:100 
Anti-Goat Alexa568 A11057 Life Technologies 1:100 
 
Table 2: Details of primary and secondary antibodies used in 
chromogenic and immunofluorescent staining of FFPE tissue samples.  
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2.8 Image Analysis 
For quantitative analysis of immunofluorescently stained CLL LN and healthy donor spleen 
tissues, three images were obtained per tissue sample for each stained and isotype section.  
These images were analysed and edited using the open source Fiji Image J software 
(Schindelin et al. 2012).  Images were adjusted for their brightness and contrast as well as 
reducing background as appropriate for each staining panel when compared to the isotype 
tissue.  Images were counted for positivity using Analyze Particles plug-in within Fiji, which 
uses an algorithm to detect boundaries of high and low fluorescence intensity and requires 
user input of size limits for “events” to be counted within each image.   Numerical data from 
these analyses were collected in Microsoft Excel for further processing and analysis.  As red 
blood cells autofluoresce across a large spectrum of fluorescence, their presence in images 
posed an issue to create false positive events during quantification.  To prevent this, the 
fluorescence channel of interest was overlaid onto the nuclear channel reading from which 
these red blood cells could be easily identified by their high fluorescence intensity across 
both channels.  This allowed their subtraction from the final quantification analysis.  
Automation of quantification was utilised where possible to ensure consistency of analysis. 
This was achieved by designing macro instructions for the Fiji Software.  Example images 
from this analysis process can be found within Appendix I. 
2.9 Statistical Analysis 
Unless otherwise indicated in Chapter 4, all non-parametric co-culture data was routinely 
analysed using the Wilcoxon signed rank test, as these experiments used paired primary 
samples.  Where appropriate, the Student’s paired t-test was used and this is noted within 
the text in Chapter 4.  Statistical significance was considered to be reached where p ≤ 0.05 
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except in instances where the control samples were used as a comparison for multiple 
samples.  In these cases, to guard against multiplicity the Bonferroni correction was applied, 
where the required p value for significance (usually ≤0.05) was divided by the number of 
samples being tested against the same control to give the new p value for significance.   For 
example, where 2 test samples were checked against a common control, significance was 
considered reached where p ≤ 0.025. 
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3.1 Introduction 
As discussed in Chapter 1, the CLL LN microenvironment is known to be the major site of 
disease progression and maintenance and whilst there are many in vitro and in vivo models 
of CLL, most do not fully represent this important niche.  A fuller understanding of the LN 
would allow the development of targeted therapies which could bring about longer 
remissions and the potential for curative therapy. 
Aside from the relative scarcity of fresh CLL LN material available, current routine practices 
for the interrogation of such tissues involve single colour immunohistochemistry (IHC).  
Whilst this may be adequate for histopathological diagnosis, single colour staining does not 
provide insight into the proportions, proximities or interactions occurring in this 
environment.  As such this study investigated the potential of utilising commercially 
available antibodies against a range of different cell markers to allow a real-world view of 
the CLL LN, highlighting not only the different cell types present but also their relationship 
to one-another.  The use of robust fluorophores and confocal microscopy allowed the capture 
of high resolution, high quality images, in turn permitting robust quantitative analysis.  The 
development of these approaches for use with formalin fixed paraffin embedded (FFPE) 
tissue also allowed a greater opportunity to access architecturally preserved high quality 
tissue (figure 6). 
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Figure 6. Cellular architecture is well preserved in FFPE tissue.  
5µm thick sections of FFPE tissues were counterstained for nuclei using 
Hoescht 33343.  Data shows representative images of CLL LN tissue from 
patient samples (n=4) with [stage of disease] in addition to healthy spleen 
tissue (n=1). 
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This study used FFPE primary LN tissue samples from seven CLL patients and FFPE healthy 
spleen tissue samples as control.  The list of patient details can be found in table 3.  Each 
patient sample, with the exception of tissue sections from Patient 3 (P3), was imaged in three 
different areas for each panel of markers being studied.  Three discrete areas were selected in 
an effort to provide a balanced insight into the cellular contents of each sample whilst 
reducing potential sampling bias which may occur with a single image.  Every effort was 
made to record images from the same three areas on serial sections stained with differing 
marker combinations.  This was facilitated by noting the shape of each tissue and seeking 
specific “landmarks” within the same regions of sequential sections such as blood vessels.   
Sample P3 had three areas collected from each of two different zones within the tissue 
(hereafter referred to as Zone 1 and Zone 2 or Z1 and Z2 respectively).  An exception was 
made for sample P3 in this way due to the striking differences seen in the architecture and 
proliferative activity (Ki-67 positivity and distribution) of the two zones within P3 tissue 
sections as described within this chapter (3.3.1).   
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Table 3. Patient information for 7 FFPE CLL LN samples used in this study . 
Patients had a mean age of 71 years at  diagnosis and 4 out of 7 patients died 5 years after diagnosis.  Key; Rx 
radiotherapy, PD post diagnosis, P/Pt patient.  
Sample Stage Sex Age Lymph Node Size Treatment Additional malignancies Death Notes
P1 A F 59 28x24x10mm N N N
P2 A M 75 20x13x6mm N
Previous Squamous Cell Carcinoma (Rx)
Basal Cell Carcinomas
Y 
(5y PD)
Pt admitted with chest infection prior to 
death
P3 A F 68 10x11x8mm N N N
Pt had flow cytometry performed on BM 
(2010) which was consistent with B-CLL. 
However, serum free-kappa (κ) & free-
lambda (λ) and κ/λ ratio normal (Oct 14)
P4 A M 85 Up to 21mm N Metastatic Squamous Cell Carcinoma (Rx)
Y 
(5y PD)
Pt breathlessness reported prior to death
P5 B M 57 20x20x20mm
Y
6x cycles FCR
N N
P6 C F 77 35x20x10mm
Y
FC therapy
N
Y 
(5y PD)
Queried Richter's transformation 2 days 
prior to death
P7 C M 76 Largest 70mm N Synchronous Transitional Cell Carcinoma
Y 
(5y PD)
In addition to CLL and TCC, Pt also had 
metatstatic oesophogeal cancer
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3.2 Chromogenic staining methods can be successfully optimised to produce 
high quality multicolour immunofluorescent images of FFPE tissue 
In order to develop a multicolour immunofluorescent staining protocol for use on FFPE CLL 
LN tissue, single colour chromogenic staining of FFPE healthy spleen tissue was first utilised 
to (i) validate antibodies being used and (ii) test the antigen retrieval and dewaxing 
techniques to be employed.  Having established these parameters single colour 
immunofluorescent stains were trialled on spleen tissue followed by combining stains into 
three-way multicolour panels for interrogation of CLL LN.  This process is outlined in 
Figures 7 and 8. 
Figure 7 shows representative images of chromogenic stained sections of FFPE healthy 
spleen tissue stained for the cell cycle activation marker Ki-67 and the T cell marker CD3.  
Following confirmation of the suitability of these antibodies and retrieval techniques, the 
methods were adapted to allow immunofluorescent staining of these markers and finally 
three-way staining of CLL LN.  As an example figure 8 shows a representative image of a 
multicolour stain on FFPE CLL LN tissue using the B cell marker PAX5, in combination with 
CD3 and Ki-67.  Additional staining panels were constructed based on this approach and 
images were subsequently quantitatively analysed using Fiji Image J Open Source software 
(see Appendix I for further details). 
In multicolour immunofluorescent staining, the order of staining was determined based 
upon the resilience of the fluorochrome-conjugated secondary antibody to light.  Primary 
antibodies for which the secondary antibody was Alexa 488-conjugated were stained for first 
as it is the most resilient to degradation, followed by Alexa 647 and finally Alexa 568.  Details 
of the antibodies used to target the different cell types are listed in table 4 below. 
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Target Cell Type/Marker 
CD3 T cell 
CD4 Th cells 
CD8a Tcyt cells 
CD68 Macrophage 
CD163 Nurse-like cells/M2 cells 
Pax5 CLL/B cells 
Ki-67 Proliferation (Cell cycle activation) 
Cleaved Caspase 3 Apoptosis (activation of the caspase pathway) 
NAMPT Nicotinamide phophoribosyl transferase enzyme 
Table 4: Details of primary antibodies used in chromogenic and 
immunofluorescent staining of FFPE tissue samples and the cell types or 
markers they represent.  
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Figure 7. Chromogenic staining of FFPE healthy spleen tissue is 
informative but requires antibody optimisation. 
FFPE healthy spleen tissue was chromogenically stained using Horse-
radish peroxidase (HRP) chromogen for the presence of different cell 
markers.  Data shows representative images of Ki-67 and CD3 staining 
taken using x40 and x10 objective lenses on an Olympus BX40 l ight 
microscope. 
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Figure 8. Multicolour immunofluorescent staining of FFPE CLL LN 
tissue shows novel insight above the capabilities of chromogenic 
staining. 
CLL LN tissue sections were stained for the expression of CD3 (green), 
PAX5 (red) and Ki67 (blue).  A representative sample (n=1) is shown. TOP: 
9 images were collated using Zeiss Zen Black software to show a 
proliferative zone.  BOTTOM: Larger view of the image within the dashed 
line on the top panel.  Images collected using x40 objective on a Zeiss 
Zen780 confocal microscope.  
100µm 
20µm 
Chapter Three – T cells and CLL cells in the LN 
72 
 
3.3 T cells and CLL cells in the proliferative CLL LN microenvironment 
As discussed in Chapter 1.4.1 a large literature has amassed on the many and varied 
potential roles of different subsets of T cells in the CLL environment and it has been shown 
that the T cell compartment in CLL is highly affected in this disease.  Consequently this 
project initially focused on the presence of T cells in the CLL LN, their relationship with CLL 
cells and the proliferative and apoptotic signature of the LN microenvironment across 
different stages of disease.  In addition, this project also investigated the balance of 
proliferation and apoptosis in the CLL LN tissue, which is markedly skewed in many cancers 
(Evan & Vousden 2001; Hanahan & Weinberg 2000).  This was achieved by utilising Ki-67 
and cleaved caspase 3 as markers of proliferation and early apoptosis respectively. 
Initially tissue samples were stained with haematoxylin and eosin dyes (H&E staining) to 
consider their morphology and to determine the presence of proliferation centres in these 
CLL LN samples.  This staining was then considered in the context of Ki-67 distribution 
within these tissues.  
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3.3.1 Ki-67 profiles of CLL LN are highly variable and evidence of “traditional” 
proliferation centres as observed by H&E are not always apparent 
Sections from seven CLL LN tissue samples and one healthy spleen tissue sample were H&E 
stained (method as described in chapter 2.7.3) to determine the presence of classical 
proliferation centres (figure 9).  These data demonstrated that all CLL LN tissues in this 
study appear to contain proliferation centres, as seen in low magnification images by 
observation of paler circular areas of tissue (figure 9).  The numbers of these centres vary 
across the CLL LN samples and appear strikingly different in sample P3 compared to the 
other tissues.  Subsequently, sections from the same seven CLL LN tissue samples and one 
healthy spleen tissue sample were then immunofluorescently stained for their expression of 
Ki-67 as a marker of active cell cycle.  There was a variation in expression of Ki-67 across the 
samples, with most showing a diffuse spread of Ki-67+ cells.  The exception to this 
observation was sample P3, within which there were two strikingly different types of 
proliferative architecture; pockets of highly Ki-67+ “proliferative” cells, denoted as Zone 1 
(Z1) and areas of low, diffuse proliferation denoted as Zone 2 (Z2) (representative images 
seen in figure 10A & B). 
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Figure 9.  H&E staining of CLL LN demonstrate varying presence of 
traditional proliferation centres.  
Sections from seven CLL LN and one healthy spleen tissue sample were 
stained with haematoxylin and eosin to investigate the ir morphology.  
Representative images are shown for each sample, labelled with patient 
code and [stage of disease].  
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Figure 10A.  CLL LN & healthy spleen show varying Ki-67 positivity. 
CLL LN and healthy spleen tissue sections were stained for the express ion 
of Ki-67 (green).  Representative images (x40 objective) are shown for 
stage A patient samples (n=4) with two images shown from sample P3, 
referred to as Zone 1 (Z1) and Zone 2 (Z2).  Samples labelled with patient 
code and [stage of disease].  Further images for later stage disease and 
healthy spleen tissue shown below.  
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Figure 10B. CLL LN & healthy spleen show varying Ki-67 positivity. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of Ki-67 (green).  Continued from figure 9A; Representative images (x40 
objective) showing Ki-67 immunofluorescent staining of stage B (n=1) & C 
(n=2) patient samples and healthy spleen tissue (n=1).  Samples labelled 
with patient code and [stage of disease].  
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Interestingly the Ki-67 distribution of these samples did not align with the presence of 
proliferation centres as seen by H&E staining, with the exception of sample P3.  Instead of 
dense areas of proliferation, the majority of these samples had a diffuse Ki-67 staining 
pattern (as seen in figure 10A&B).  This is perhaps unexpected as many groups discuss high 
prevalence of PC within the CLL LN and to a lesser extent the BM (Chapter 1.5.1) (Schmid & 
Isaacson 1994; Bonato et al. 1998; Ciccone et al. 2012; Plander et al. 2009).  The data shown 
here may highlight that these proliferation centres may be a misnomer. 
Based on these data, the Z1 areas seen within sample P3 may represent very early stage A 
disease, where the germinal centre (GC) architecture of the previously healthy LN has not 
yet been fully disrupted by the CLL tumour clone.  In this scenario, rather than being a 
marker of CLL disease, the GC (potentially subsequently labelled a putative PC) actually 
represents the remnants of the healthy tissue and architecture.   
Overall the Ki-67 expression of the seven CLL LN samples varied greatly and did not appear 
to correlate to disease stage (figure 11). 
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Figure 11.  Ki-67 positivity in CLL LN and healthy spleen is diverse and 
not related to stage of disease.  
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for the expression of Ki -67.  Three areas 
from each tissue were imaged (with the exception of sample P3, which had 
3 areas images from each of Z1 and Z2) and these images were 
quantitatively analysed for Ki67 positivity using Fiji Image J analysis 
software.  Numbers of positive cells were averaged across the three images 
collected for each sample and mean data is plotted with S.E.M.  Samples 
are labelled with [stage of disease] along the x-axis. 
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3.3.2 PAX5 expression and PAX5+Ki67+ cells within the CLL LN decrease associated with 
stage of disease 
In conjunction with the Ki-67 observations described above, sections were stained for the 
presence of CLL cells using the pan-B cell marker PAX5 (figure 11A & B).  As described in 
Chapter 1.1.1 PAX5 is an important B cell transcription factor responsible for the correct 
development of B cells (Cobaleda et al. 2007) and has been used routinely as a marker of CLL 
cells and in the diagnosis of B cell lymphomas (Torlakovic et al. 2002).  Two significant 
findings were noted from interrogation of these tissues with the combination of PAX5 and 
Ki-67.  
Firstly, it was noted that the presence of PAX5+ cells within the CLL LN decreases in 
correlation to stage of disease (figures 13 & 14).  Initially this suggested that the numbers or 
density of tumour cells within the LN reduce as disease progresses.  However this is 
questionable and the data more likely indicates that expression of PAX5 reduces as disease 
progresses.  This may have important implications for the understanding of CLL biology. 
Furthermore, there was also a marked decrease in PAX5+Ki-67+ cells in the CLL LN 
correlated to disease stage (figures 13 & 14).  This was more than the general decrease seen in 
PAX5 expression as described above and so cannot be explained by this observation alone.  
As such, these data may indicate that there is a relative decrease in the number of Ki-67+ CLL 
cells in the CLL LN or, more feasibly, that the expression of PAX5 in proliferating tumour 
cells significantly decreases as in later stage disease.  Although the numbers of tissues are 
small, these observations indicate the changing biology of CLL cells in situ during disease 
progression. 
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Figure 12A. CLL cells in the LN and B cells in healthy spleen are PAX5 + 
and dual staining of PAX5+Ki-67+ cells can be determined. 
CLL LN and healthy spleen tissue sections were stained for the  expression 
of PAX5 (red) and Ki-67 (green).  Representative images (x40 objective) are 
shown for stage A patient samples (n=4).  Samples labelled with patient 
code and [stage of disease].  Further images for later stage disease and 
healthy spleen tissue shown below. 
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Figure 12B.  CLL cells in the LN and B cells in healthy spleen are Pax5 + 
and dual staining of Pax5+Ki-67+ cells can be determined. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of PAX5 (red) and Ki-67 (green).  Continued from figure 12A; 
Representative images (x40 objective) are shown for stage B (n=1) & C 
(n=2) patient samples and healthy spleen tissue (n=1). Samples labelled 
with patient code and [stage of disease].  
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Figure 13. PAX5+expression is variable but decreases as disease 
progresses. 
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for expression of PAX5. Three areas 
from each tissue or zone were imaged and quantitatively analysed for 
PAX5 positivity using Fiji Image J analysis software. Upper graph; Mean 
Fluorescence Intensity values were averaged across the three images and 
mean data are plotted ±S.E.M. Samples labelled with [stage of disease] 
along the x-axis. Lower graph; Mean Fluorescence Intensity values for 
early (stage A (n=4)) and late (stage B & C (n=3)) samples were collated 
and mean data plotted ±S.E.M. 
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Figure 14. PAX5+ Ki67+ expression is variable but decreases as disease 
progresses. 
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for expression of PAX5 (pan-B cell) and 
Ki-67(active cell cycle). Three areas from each tissue or zone were imaged 
and quantitatively analysed for dual positivity for PAX5 and Ki -67 using 
Fiji Image J analysis software. Upper graph; numbers of dual positive cells 
were averages across the three images and mean data are plotted ±S.E.M. 
Samples labelled with [stage of disease] along the x -axis. Lower graph;  
numbers of dual positive cells for early (stage A (n=4)) and late (stage B & 
C (n=3)) samples were collated and mean data plotted ±S.E.M.  
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3.3.3 T cells are dispersed within the CLL LN at all stages of disease and proliferating CLL 
cells frequently appear to be localised close to T cells 
Following the observations of PAX5 and Ki-67 positivity in the LN, CLL tissue sections were 
stained with these markers in combination with the pan-T cell marker CD3 to observe the 
proportions and distribution of T cells in the niche in relation to proliferative CLL cells 
(figure 15A & B). 
As may be expected these data indicate that T cells are present in the CLL LN at all stages of 
disease, although when quantitated it was noted that there was a high level of variability in 
CD3 expression across the samples (figure 16).  This variability is particularly striking in 
early stage disease samples.  When considering the distribution of CD3 cells within these 
tissues, the variability seen from quantification likely reflects the presence of T cell rich and T 
cell poor areas within the tissues.  This, particularly in early stage disease, may reflect the 
remnants of the healthy LN architecture, where distinct T cell and B cell zones are found 
within the tissues (figure 17).  In particular, consideration of the variability seen within the 
sample P3 in combination with previous Ki-67 distribution data further supports the concept 
that this sample is a very early stage CLL, which has distinct T and B cells zones remaining 
in the LN tissue. 
Despite the variability, it was observed from these multicolour images that Ki-67+ positive 
CLL cells were frequently adjacent to T cells (figure 18) supporting the in vitro literature 
indicating that T cells can provide pro-survival and pro-proliferative signals to CLL cells.   
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Figure 15A. T cell presence in CLL LN and healthy spleen tissue shows 
close proximity to proliferative CLL cells.  
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD3 (green), PAX5 (red) and Ki-67 (blue).  Representative images (x40 
objective) are shown for stage A patient samples (n=4).  Samples labelled 
with patient code and [stage of disease].  Further images for later stage 
disease and healthy spleen tissue shown below.  
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Figure 15B. T cell presence in CLL LN and healthy spleen tissue shows 
close proximity to proliferative CLL cells.  
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD3 (green) PAX5 (red) and Ki-67 (blue).  Continued from figure 15A; 
Representative images (x40 objective) are shown for immunofluorescent 
staining of stage B (n=1) & C (n=2) patient samples and healthy spleen 
tissue (n=1).  Samples labelled with patient code and [stage of disease].  
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Figure 16. Average numbers of CD3+ T cells vary across all stages of CLL 
disease and variability of expression is also seen within samples.  
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for the expression of CD3.  Three areas 
from each tissue were imaged (with the exception of sample P3, which had 
3 areas images from each of Z1 and Z2) and these images were 
quantitatively analysed for CD3 positivity using Fiji Image J analysis 
software.  Numbers of positive cells were averaged across the three images 
collected for each sample and mean data is plotted with S.E.M.  Samples 
are labelled with [stage of disease] along the x-axis. 
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Figure 17. CD3 positive cells vary greatly in numbers within a single 
CLL LN sample. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD3 (green) and showed variability in expression between the three 
images from each sample.  The three immunofluorescent staining images 
(x40 objective) are shown for sample P3 Z2 and demonstrate the variability 
in the presence of T cells within the same tissue. Samples labelled with 
patient code, [stage of disease] and area number.  
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Figure 18. Localisation of Ki-67+ CLL cells in the CLL LN in relation to T 
cells. 
Seven CLL LN tissue sections were stained for the expression of CD3 
(green), PAX5 (red) and Ki-67 (blue).  Representative images (x40 
objective) are shown for stage A (n=4), stage B (n=1) and stage C (n=2) 
patient samples.  Samples labelled with patient code and [stage of 
disease].  These images demonstrate the close proximity of CD3 + cells 
(green) to Ki67+PAX5+ cells (pink/purple).  
 
10µm 
P1 [A] P2 [A] 
P3 Z1 [A] P3 Z2 [A] 
P4 [A] P5 [B] 
P6 [C] P7 [C] 
10µm 
10µm 
10µm 
10µm 10µm 
10µm 10µm 
Chapter Three – T cells and CLL cells in the LN 
90 
 
3.4 T cell subsets in the CLL LN 
Following the observations in chapter 3.3 and considering the current literature regarding 
the impact of CLL on the T cell compartment (Chapter 1.4.1) the tissues were stained to 
determine the subtypes of T cells seen within the CLL LN.  
CLL and healthy spleen sections were stained for the presence of T cell subtypes using a 
combination of CD3, CD4 and CD8 antibodies (figure 19A & B).  The dual positivity of the 
pan-T cell marker CD3 with the subtype marker CD4 denoted the presence of T helper cells 
(Th), whilst dual positivity of CD3 with CD8 denoted the presence of cytotoxic T cells (Tcyt).  
As noted previously when considering the total T cell presence in the CLL LN, there was 
variability seen in the expression of T cell subtype markers CD4 and CD8, particularly 
during early stage disease (figure 20). 
Whilst expression in these tissues does not appear to link to stage of disease, the spatial 
patterns of the global CD3+ and CD3+CD8+ T cells in the CLL LN intimate that stage A CLL 
LNs retain some of the architecture of the healthy node (figure 21) although this would need 
to be confirmed on further tissue samples. 
Overall these data indicated that both Tcyt and Th cells are present in the CLL LN at all stages 
of disease and the relative prevalence of these subtypes varies from patient to patient 
irrespective of disease stage.  In addition, the architecture of the LN is progressively altered 
as disease advances which is reflected by the spatial distribution of T cell subtypes within the 
tissue and may suggest a significant change in the roles played by these cell types within the 
disease. 
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Figure 19A. The balance of CD4+ and CD8+ T cell subsets within CLL LN 
and healthy spleen tissue is variable and does not correlate to stage of 
disease. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD3 (red), CD4 (green) and CD8 (blue).  Representat ive images (x40 
objective) are shown for stage A patient samples (n=4).  Samples labelled 
with patient code and [stage of disease].  CD3 (red) co -localises with either 
CD4 (yellow) denoting Th cells or CD8 (pink) denoting Tcyt  cells.  Further 
images for later stage disease and healthy spleen tissue shown below.  
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Figure 19B. The balance of CD4+ and CD8+ T cell subsets within CLL LN 
and healthy spleen tissue is variable and does not correlate to stage of 
disease. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD3 (red), CD4 (green) and CD8 (blue).  Continued from figure 18A; 
Representative images (x40 objective) are shown for immunofluorescent 
staining of stage B (n=1) & C (n=2) patient samples and healthy spleen 
tissue (n=1).  Samples labelled with patient code and [stage of disease].  
CD3 (red) co-localises with either CD4 (yellow) denoting T h cells or CD8 
(pink) denoting Tcyt cells. 
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Figure 20. Presence of T cell subtypes is variable across CLL LN samples 
unrelated to stage of disease, with high variability of expression within 
samples also seen in early stage disease.  
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for the expression of CD3, CD4 and 
CD8.  Three areas from each tissue were imaged (with the exception of 
sample P3, which had 3 areas images from each of Z1 and Z2) and these 
images were quantitatively analysed for CD3 +CD4+ or CD3+CD8+ dual 
positivity using Fiji Image J analysis software.  Numbers of positive cells 
were averaged across the three images collected for each sample and mean 
data is plotted with S.E.M.  Samples are labelled with [stage of disease] 
along the x-axis. 
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Figure 21. Spatial distribution of T cyt in the CLL LN may relate to stage 
of disease and account for variability during quantification.  
CLL LN tissue sections were stained for the expression of CD3 (red) and 
CD8 (blue).  Representative images (x10 objective) are shown for a single 
stage A patient (n=1) and a single stage C patient (n=1).  Samples labelled 
with patient code and [stage of disease].  Images display the difference in 
spatial distribution of Tcyt cells (pink/purple) in early v.s. late CLL LN 
tissues. Late stage disease appears to lose organised structure of T cell 
zones. 
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3.5 The balance of proliferation and apoptosis in the CLL LN 
It is commonly reported that the balance of proliferation and apoptosis is skewed to favour 
disease progression in many cancers (Hanahan & Weinberg 2000; Evan & Vousden 2001).  By 
studying a combination of the cell cycle activation marker Ki-67 and cleaved caspase 3, a 
marker for early apoptosis, this study sought to determine whether there was a difference in 
the balance of proliferation and apoptosis in this cohort of patient samples. 
CLL LN samples and healthy spleen control tissue were stained for their expression of Ki-67 
and cleaved caspase 3 in combination with PAX5 (figure 22A & B).  Strikingly, the levels of 
expression of cleaved caspase 3 across all CLL LN tissues was markedly lower than that seen 
within healthy spleen, and within the proliferative zone of sample P3 (figure 23).  It should 
be noted from the literature that healthy lymph node tissues are reported to have relatively 
high expression levels of cleaved caspase 3 when compared to healthy spleen tissue; between 
25-75% of germinal centre cells and up to 25% of non-germinal centre cells in lymph node 
tissues express caspase 3 compared to up to 25% of cells in the red pulp and rare in the white 
pulp within spleen tissue (Ponten et al. 2008).  When the data herein is considered in context 
of this literature, it is even more striking to note that the CLL lymph node tissue (with the 
exception of P3) have such a reduced expression of cleaved caspase 3 compared to the 
healthy spleen control. 
Whilst expression of cleaved caspase 3 alone was informative, this staining was further 
interrogated by comparing relative levels of cleaved caspase 3 and Ki-67 expression within 
each tissue (figure 24, top graph).  When comparing this ratio of proliferation to apoptosis in 
healthy spleen tissue and CLL LN tissue, it was apparent that the balance in CLL LN tissue 
at all stages greatly deviates from this study’s example of normal homeostasis (healthy 
spleen).  When the lymph node tissue values were normalised to healthy spleen (figure 24, 
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bottom graph where spleen ratio value= 1.0) it became clear that within different stages of 
CLL disease, this proliferation and apoptosis ratio is very variable.  The ratio within sample 
P3 (Z1 & Z2) were the lowest seen across the different CLL tissues and closest to the healthy 
spleen control (i.e. indicating that levels of proliferation are only slightly higher than levels of 
apoptosis).  Once again this supports the concept that sample P3 may represent very early 
stage A disease.  Despite this similarity, there is still a greater than 10 fold difference in the 
ratio between P3 Z2 and the healthy spleen sample (13.5 v.s. 1.0).  Overall, these results 
suggest that the global balance of apoptosis within the CLL LN is significantly disrupted 
compared to healthy tissue and that this disruption occurs even from a relatively early stage 
of disease. 
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Figure 22A. CLL samples have variable levels of cleaved caspase 3 and 
Ki-67 seemingly unrelated to disease stage. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of Ki-67 (green) PAX5 (red) and cleaved caspase 3 (blue).  Representative 
images (x40 objective) are shown for stage A patient samples (n=4).  
Samples labelled with patient code and [stage of disease].  Further images 
for later stage disease and healthy spleen tissue shown below.  
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Figure 22B; CLL samples have variable levels of cleaved caspase 3 and 
Ki-67 seemingly unrelated to disease stage. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of Ki-67 (green) PAX5 (red) and cleaved caspase 3 (blue).  Continued from 
figure 22A; Representative images (x40 objective) are shown for 
immunofluorescent staining of stage B (n=1) & C (n=2) patient samples 
and healthy spleen tissue (n=1).  Samples labelled with patient code and 
[stage of disease].  
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Figure 23. Typically low level average expression of cleaved caspase 3 in 
CLL LN tissues compared to healthy spleen.  
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for the expression of cleaved caspase 3.  
Three areas from each tissue were imaged (with the exception of sample 
P3, which had 3 areas images from each of Z1 and Z2) and these images 
were quantitatively analysed for cleaved caspase 3 positivity using Fiji 
Image J analysis software.  Numbers of positive cells were averaged across 
the three images collected for each sample and mean data is plotted with 
S.E.M.  Samples are labelled with [stage of disease] along the x -axis. 
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Figure 24.  The ratio of proliferation to apoptosis reveals a broad but 
variable aberration in CLL compared to healthy tissue.  
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for expression of cleaved caspase 3 and 
Ki-67.  Three areas from each tissue were imaged (with the exception of 
sample P3 which had 3 areas images from each of Z1 and Z2) and these 
images quantitatively analysed for positivity using Fiji Image J analysis 
software.  Average numbers of positive cells from the three images 
collected for each sample and mean data used to determine a ratio of 
proliferative to apoptotic cells.  Upper graph : Ratio for each tissue (mean 
Ki-67/mean cleaved caspase 3) Lower graph: Ratio for each CLL patient 
normalised to healthy spleen tissue (healthy spleen = 1.0).  Samples are 
labelled with [stage of disease] along the x-axis. 
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3.6 Discussion 
The data collated herein have demonstrated that archived FFPE CLL LN samples can be 
used to produce robust data via multicolour immunofluorescent staining and quantitative 
analysis and promotes the ongoing development of these techniques for future studies.  The 
use of these samples has allowed insight into CLL disease biology which cannot be 
recapitulated by in vitro or in vivo animal studies and as such advocates the use of these 
methods in combination with other techniques to allow a fuller understanding of the disease 
to be developed. 
In addition to the development of these methods, this work has produced several key 
findings.  Firstly, the Ki-67 profiles of these CLL LN tissues have raised queries over the 
structure and composition of proliferation centres in these tissues.  Whilst H&E staining data 
collected in this study confirm the presence of traditional proliferation centres, it appears 
that Ki-67 positive cells in the CLL LN are typically diffusely spread and their prevalence is 
unrelated to disease stage.  These data indicate that traditional PC presence in the LN may 
not represent areas of intense proliferation.  As reports of PC in LN continue to be referenced 
in the literature and their size has been correlated to aggressiveness of disease (Ciccone et al. 
2012) these data may suggest that PC represent areas of localised interactions between CLL 
cells and microenvironmental cells, rather than areas of intense proliferation.  In this 
scenario, PC in the LN would indicate pro-survival areas, rather than pro-proliferative areas.   
Secondly it was shown that there is a decrease in the expression of PAX5 as stage of disease 
progresses, likely a reflection of a reduced expression of PAX5 within tumour cells.  This 
appears particularly prevalent within the proliferative CLL cell population and this 
hypothesis is more likely than the premise that disease progression leads to a reduction in 
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tumour cell presence in the LN.  Reduced PAX5 expression has been reported within other B 
cell tumours and is linked to more aggressive disease (Teo et al. 2015).   
In addition, these data demonstrated the prevalence of T cells within the CLL LN regardless 
of stage of disease and showed infiltration of these cells throughout the tissues.  Furthermore 
it was shown that in all patient samples, Ki-67+ CLL cells were commonly found adjacent to 
T cells indicating a likely interaction occurring in vivo.  Finally, whilst the total numbers of T 
cell subsets did not link to stage of disease in this study, it was noted that the spatial 
distribution of T cells in these tissues appears to alter as disease progresses and likely reflects 
the changing global architecture of the node and the cells within.   
The ratio of proliferation to apoptosis in these tissues is also relatively variable but suggests 
that the balance of these processes in CLL is skewed compared to healthy tissue (Ponten et 
al. 2008).  In context of proliferation data collected by (Messmer et al. 2005) utilising heavy 
water, these data also suggest that the LN microenvironment is highly protective towards 
CLL cells and that significant levels of tumour cell death must be occurring in the periphery.   
Subsequent work focused upon the role of the T cell in the LN microenvironment, with an in 
vitro assay being constructed to observe the impact of CLL cells on T cells and vice versa.  
These data are described in the following chapter. 
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4 T CELLS AND CLL CELLS IN VITRO 
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4.1 Introduction 
As described in Chapter 1, T cell interactions with CLL cells in the LN are thought to 
produce important pro-survival and pro-proliferative signals within CLL cells.  The data 
presented in Chapter 3 further support this concept showing that T cells and CLL cells 
within the LN niche reside in close proximity and Ki-67+ CLL cells are typically adjacent to T 
cells (also shown here in figure 25). 
As also outlined in Chapter 1.7.1 several studies have attempted to address the biology of 
CLL cell-T cell interactions using either autologous or allogeneic T cell and CLL co-cultures.  
This chapter presents new observations obtained using CLL cell-allogeneic T cell co-cultures 
and has implications for the interpretation of these types of studies in the future.  
In the outset the response of CD4+ T cells to antigenic stimulation by CLL cells was 
investigated.  The experiments set out to determine whether CLL cells induce a proliferative 
response in allogeneic T cells.  
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Figure 25. Proliferative CLL cells in the CLL LN commonly reside in 
close proximity to T cells at all stages of disease.   
CLL LN tissue sections were stained for the expression of CD3 (green), 
PAX5 (red) and Ki-67 (blue).  Representative images (x40 objective) are 
shown for stage A (n=2) stage B (n=1) and stage C (n=1) patient samples.  
Samples labelled with patient code and [stage of disease].  Images 
highlight the prevalence of proliferative CLL cells (pink/purple) being in 
close proximity to T cells (green) across a range of disease stages.  The 
white dashed line denotes the different zones within sample P3.  
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4.2 Irradiated CLL cells induce healthy donor allogeneic CD4+ T to incorporate 
3H-thymidine  
An established method for measuring cell proliferation in-vitro is the incorporation of 3H-
thymidine into newly synthesised DNA (Taylor et al., 1957).  In this assay a given pulse of 
3H-thymidine allows the determination of the relative populations of cells in S-phase of the 
cell cycle across different experimental groups within a given experiment.  3H-thymidine 
incorporation was therefore used to assess the impact of CLL cells on allogeneic T cell 
proliferation in a co-culture system. 
CLL cells were first irradiated to render them mitotically incompetent (Noorizadeh et al. 
2004) and subsequently mixed at a 1:1 ratio with magnetically purified healthy donor 
allogeneic CD4+ T cells (hdaCD4+ T cells) and co-cultured.  3H-thymidine was pulsed into 
relevant wells 24 hours prior to harvest on 7 consecutive days and its incorporation analysed 
(figure 26).  Despite the heterogeneity of 3H-thymidine incorporation, co-cultured wells (red) 
showed a significantly larger incorporation of 3H-thymidine at day 7 when compared to 
irradiated CLL cells alone (green) or hdaCD4+ T cells alone (blue).  Statistical significance 
was shown across all 4 co-cultures when compared to hdaCD4+ T cell alone at day 7 
(p=0.011, 0.038, 0.017 and 0.013 respectively using a students paired t-test).  Mean data from 
n=18 samples and n=9, at days 5 and 7 respectively (figure 27) showed a similar trend and 
were also highly significant (p=0.0027 and 0.00018 using Wilcoxon signed rank test).  
Subsequent assays were predominantly measured at day 5 alone.  Initial interpretation of 
these data indicated that the co-culture of hdaCD4+T cells with division incompetent CLL 
cells induced marked T cell proliferation as measured by uptake of 3H-thymidine. 
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Figure 26. HdaCD4+T cells incorporated 3H-thymidine when cultured 
with irradiated CLL cells.  
HdaCD4+ T cells and irradiated CLL cells were each seeded at 
2.5x105cells/well either in combination or alone.  Wells were pulsed with 
3H-thymidine 24 hours prior to harvest and harvested every 24 hours for 7 
days.  Data is the mean of triplicate wells ±S.E.M.  Experiments were set 
using four different CLL samples and 2 different hdaCD4 +Tcell samples.  
Note that different scales are used on each “y” axis which reflects the 
variation in 3H-thymidine incorporation between different CLL and 
hdaCD4+ T cell co-cultures.  The difference in 3H-thymidine incorporation 
between co-culture and hdaCD4+ T cell alone wells showed statistical 
significance at day 7 in all cases (student’s t-test, p values shown on each 
graph). 
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Figure 27. 3H-thymidine assay showed significant difference in 
incorporation at day 5 and day 7 of co-culture. 
HdaCD4+ T cells were cultured with irradiated CLL cells, each seeded at 
2.5x105cells/well in triplicate.  Wells were pulsed with 3H-thymidine 24 
hours prior to harvest and incorporation was assessed at day 5 (left) and 
day 7 (right).  Average 3H-thymidine incorporation is plotted ±S.E.M. for 
hdaCD4+ T cells alone (-CLL (i)) vs. co-culture wells (+CLL (i)).  Data 
represents n=18 & 9 samples at day 5 and 7 respectively and differences in 
incorporation were highly significant at both time points (p<0.005).  
 
 
 
 
 
 
 
 
 
0
5000
10000
15000
20000
25000
- CLL (i) + CLL (i)
0
5000
10000
15000
20000
25000
- CLL (i) + CLL (i)
3
H
-t
h
y
m
id
in
e
 I
n
co
rp
o
ra
ti
o
n
 (
C
P
M
) 
p=0.0027 p=0.00018 
Day 5 Day 7 
Chapter Four – T cells and CLL cells in vitro 
109 
 
4.3 Purification of the CLL samples prior to irradiation and culture significantly 
affects the incorporation of 3H-thymidine by co-cultured cells 
 
The above experiments utilised unpurified mononuclear cell (MNC) CLL preparations.  
Whilst the CLL samples used in all co-culture experiments had a minimum CD19+ purity of 
75% (as routinely tested by flow cytometry) the impact of the non-CLL MNC fraction within 
the co-culture was investigated.  3H-thymidine was again employed to determine whether 
the incorporation response in co-culture wells was altered by purification of the CLL MNC.  
Prior to their irradiation CLL samples were positively or negatively purified (as described in 
Chapter 2.2.3).  Samples were tested for CD19+ purity by flow cytometry pre- and post-
purification (figure 28).  Purified or non-purified irradiated CLL cells from the same samples 
were subsequently mixed with hdaCD4+ T cells and cultured.  3H-thymidine incorporation 
was measured at day 5 (figure 29).  Co-cultures containing purified CLL cells had a 
significantly lower level of 3H-thymidine incorporation compared to non-purified CLL MNC 
samples.  These data suggested that the hdaCD4+ T cells proliferate more in the presence of 
non-purified CLL samples, and whilst purified CLL cells were also able to induce significant 
3H-thymidine incorporation during co-culture, this indicates a significant role for non-CLL 
MNC in the activation of T cells with potential implications for the CLL LN 
microenvironment. 
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Figure 28 Flow cytometry analysis of CLL sample CD19 purity.  
CLL samples were routinely tested for their CD19 purity before and after 
purification steps. Representative images show a single CLL sample tested 
for purity pre- and post- positive selection purification. (A) Samples were 
viably gated using the FSC/SSC profile and (B) viable cells were 
subsequently tested for their CD19/CD3 positivity. Representative images 
for negative selection can be found in Appendix I.  
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Figure 29. Purification of CLL samples significantly affected co-culture 
3H-thymidine incorporation. 
HdaCD4+ T cells were cultured with either unpurified irradiated CLL 
samples or purified irradiated CLL cells, each seeded at 2.5x105cells/well 
in triplicate.  Wells were pulsed with 3H-thymidine 24 hours prior to 
harvest and incorporation was assessed at day 5.  Data shown here 
represents the average 3H-thymidine incorporation of co-culture wells 
plotted ±S.E.M. for n= 8 samples (CLL samples were either positively or 
negatively purified as described in Chapter 2 .2.3). 
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4.4 Purification of CLL samples also significantly affects their incorporation of 
3H-thymidine in response to CD40L stimulation 
The data above showed that CLL cell enrichment had an impact on co-culture incorporation 
of 3H-thymidine which was deemed to be an indicator of reduced hdaCD4+ T cell 
proliferation.  These data showed that the presence of non-CLL MNC from CLL MNC 
preparations induced a greater incorporation of 3H-thymidine in co-culture wells than 
purified CLL cells alone induced.  These data do not clearly demonstrate whether the non-
CLL MNC have a direct impact upon the T cell population or whether they impact the CLL 
cells and augment a CLL cell-induced T cell proliferation.  It should be noted that following 
purification, CLL samples still contained a small proportion of contaminant cells (~3.5%, 
figure 28) and this cannot be ruled out as the source of the induced 3H-thymidine 
incorporation in purified co-culture wells.  To better determine whether the non-CLL MNC 
might interact with CLL cells in co-culture, non-CLL MNC were tested for their ability to 
affect CLL cell proliferation.  CLL cells were cultured using a stromal T cell mimetic assay to 
induce proliferation.  CD40L is an important T cell derived stimulatory signal and has been 
routinely used in previous studies by this group and others to stimulate CLL cell 
proliferation in-vitro (Hayden et al. 2009; Pascutti et al. 2013).  
Purified or whole CLL MNC samples were cultured on CD40L expressing stromal cells (L-40 
stroma, described in Chapter 2.3).  In these experiments CLL cells were left un-irradiated to 
allow their proliferation.  3H-thymidine incorporation was measured at day 5 (figure 30) and 
demonstrated that purified CLL cells showed a significantly reduced incorporation of 3H-
thymidine compared to unpurified samples (p=0.025).  It should be noted that a stroma alone 
control was always included in these experiments to ensure that Mitomycin C treatment of 
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the stroma (to prevent their proliferation and subsequent uptake of 3H-thymidine as 
described in chapter 2.3.3) was successful. 
This data shows that CLL cell proliferation following CD40L stimulation is enhanced by the 
presence of non-CLL MNC indicating a significant role for other cell types in the LN 
microenvironment and supporting the data seen in co-cultures above.  This observation 
resonates with recent reports of Nurse-like Cells (NLC) in the CLL LN (as discussed in 
Chapter 1.5.3) and were the reason behind the studies described later in Chapter 5. 
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Figure 30. Purification of CLL samples significantly affected 3H-
thymidine incorporation during T cell signal derived stimulation.  
CD19+ purified and untouched cells from the same CLL samples were 
seeded at 2.5x105cells/well in triplicate onto L-40 stroma.  Wells were 
pulsed with 3H-thymidine 24hrs prior to harvest and incorporation was 
assessed at day 5.  Data is the average 3H-thymidine incorporation of n=3 
samples and is plotted ±S.E.M. 
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4.5 Co-cultured cells have improved viability however 3H-thymidine 
incorporation seen in co-cultures does not relate to cell proliferation 
The above experiments appeared to indicate a proliferative response by hdaCD4+ T cells in 
response to CLL MNC, albeit enhanced by the presence of non-CLL cell MNC in the 
irradiated samples.  Whilst T cell-driven proliferation of CLL cells is widely accepted to 
occur in the CLL LN and appears to be supported by the staining of CLL LN shown in 
Chapter 3 and here in figure 4.1, to what extent CLL cells and T cells induce reciprocal 
proliferation in the same interaction is uncertain.  The relatively small number of Ki-67+ T 
cells in CLL LN in Chapter 3 (figure 15) questioned the apparent proliferation of hdaCD4+ T 
cells in response to CLL MNC seen in these in vitro co-cultures. 
The above experiments employed irradiated CLL MNC in order to restrict 3H-thymidine 
incorporation to the T cells.  However, use of non-irradiated CLL MNC permitting the 
mutual responses of both cell types to be observed would better reflect the in vivo situation.  
An assay was therefore developed to allow simultaneous measurement of T cell and CLL 
MNC proliferation.  
4.5.1 Viability 
As the LN microenvironment has a pro-survival effect upon CLL cells in addition to the pro-
proliferative effect, viability within the co-culture was also tested.  Furthermore since Tfh 
cells, which reside in the LN, have been shown to support CLL cell proliferation in vitro 
through the secretion of IL-21 recombinant human IL-21 was added to co-cultures.  This was 
deemed relevant because culture volumes used in the experiments would greatly dilute any 
endogenous IL-21 produced in vitro. 
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HdaCD4+ T cells and CLL MNC were cultured alone and together for five days in the 
presence of IL-21.  Cells were harvested and propidium iodide incorporation (PI) was 
measured in combination with CD4 and CD19 expression using flow cytometry (figure 31).  
PI is excluded from viable cells by an efficient efflux mechanism and therefore an increase in 
PI positivity denotes reduced viability.  The data indicates that co-culture of hdaCD4+ T cells 
and CLL MNC significantly reduced the incorporation of PI by CD19+ CLL cells and CD4+ T 
cells (figure 32).  As such, co-culture sustained the viability of both CLL cells and T cells 
compared to their culture alone thereby supporting the concept of reciprocal interactions 
between CLL cells, the CLL MNC and T cells in the CLL LN. 
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Figure 31. HdaCD4+T cell and CLL cell co-culture viability is improved 
compared to either cell type cultured alone.  
HdaCD4+ T cells were cultured alone or in combination with CLL MNC, 
each seeded at 2.5x105 cells/well in triplicate in the presence of IL-21.  All 
wells were harvested at day 5 and pooled triplicate wells were analysed 
via flow cytometry for their expression of CD19, CD4 and incorporation of 
propidium iodide.  Representative flow cytometry data shown (n=1). 
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Figure 32. Reduction in Propidium Iodide incorporation by co-cultured 
CLL cells and hdaCD4+ T cells in comparison to culturing alone 
indicates improved viability.  
HdaCD4+ T cells were cultured alone or in combination with CLL cells, 
each seeded at 2.5x105 cells/well in triplicate in the presence of IL-21.  All 
wells were harvested at day 5 and pooled triplicate wells were analysed 
via flow cytometry for their expression of CD19, CD4 and incorporation of 
propidium iodide.  Data represents the average propidium iodide 
incorporation of CD19+ and CD4+ cells during co-culture compared to their 
culture alone.  Data represents n=3 samples ±S.E.M.  
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4.5.2 Proliferation 
To monitor cellular proliferation, the viable cell fluorescent labels CellTrace™ CFSE and 
CellTrace™ Far Red were utilised (Lyons, 1999).  In this approach each cellular division 
reduces the fluorescence intensity of the labelled cells, which can be measured by flow 
cytometry.  Parallel staining CLL MNC with one label and T cells with the other rendered it 
possible to observe cell division in each population following co-culture. 
HdaCD4+ T cells and CLL MNC were CellTrace™ labelled prior to their culture and a base 
line fluorescence intensity reading taken at day zero (figure 33).  Following five days of 
culture cellular proliferation was measured (figures 34 & 35) against the baseline values.  In 
addition, cultures were monitored to determine what proportions of the cells were in active 
cell cycle (figure 36).   
Unexpectedly, these data demonstrated that co-culture of hdaCD4+ T cells and CLL MNC 
does not induce strong proliferation of either cell type.  This was supported by cell cycle 
analysis that demonstrated co-cultures had a quiescent cell cycle profile, as revealed by a 
dominant Go/G1 population and lack of cells in S and G2/M phases of the cell cycle.  The lack 
of detection of cycling cells was not technical since cell proliferation by CellTrace™ detection 
and cell cycle activity was readily observed in CLL MNC that had been cultured on L-40 
stroma (figures 34, 35 & 36).  It should be noted that there does appear to be a very small 
number of hdaCD4+ T cells that have a reduced CellTrace™ Far Red signal (figure 34) 
although this is only slightly above that seen in T cell alone wells (figure 35) and was difficult 
to align with previously reported 3H-thymidine incorporation data. 
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Figure 33. Optimisation of CellTraceTM labelling to monitor 
proliferation. 
Prior to culture hdaCD4+ T cells and CLL MNC were labelled with 
different CellTrace™ dyes.  Cells were analysed by flow cytometry at Day 
0 to allow a base line fluorescent signal to be determined.  This baseline 
was gated (R1/R7) and used in subsequent analyses to determine the 
proliferation status of hdaCD4+T cells and CLL MNC during culture.  
Representative data shown; CLL MNC labelled with CellTrace™ CFSE and 
hdaCD4+ T cells labelled with CellTrace™ Far Red fluorescent dyes.  
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Figure 34. Flow cytometry analysis of CellTraceTM fluorescence intensity.  
Prior to culture hdaCD4+ T cells were labelled with CellTrace™ Far Red 
and CLL MNC with CellTrace™ CFSE to monitor cellular proliferation.  
Representative data shown for both dyes of; co -culture of hdaCD4+ T cells 
and CLL MNC, hdaCD4+ T cells alone, CLL MNC alone on L-40 stroma and 
L-cont stroma.  Cells were each seeded at 2.5x105cells/well in triplicate in 
the presence of IL-21 and harvested at day 5.  R1 and R7 gates were 
determined as previously described.  Proliferation rates were calculated 
using gates R2-R6 (CLL MNC) and R8-R12 (hdaCD4+ T cells). 
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Figure 35. Analysis of cellular proliferation using CellTrace™ 
fluorescent dyes indicates an absence of strong proliferation in co-
culture wells. 
Prior to culture hdaCD4+ T cells were labelled with CellTrace™ Far Red 
and CLL MNC with CellTrace™ CFSE to monitor cellular proliferation.  
Cells were cultured in the following conditions; co-culture of hdaCD4+ T 
cells and CLL MNC, hdaCD4+ T cells alone, CLL MNC alone on L-40 
stroma and L-cont stroma.  Cells were each seeded at 2.5x10 5cells/well in 
triplicate in the presence of IL-21 and harvested at day 5.  Data shown are 
the analysis of events in gates R1-R12 as shown in figure 33. 
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Figure 36. Cell cycle analysis indicates a quiescent profile in co -cultures. 
HdaCD4+ T cells and CLL MNC were cultured alone or in combination 
each seeded at 2.5x105 cells/well in triplicate in the presence of IL-21.  All 
wells were harvested at day 5 and pooled triplicate wells were incubated 
with cell cycle buffer containing PI to monitor cell cycle activity.  
Representative data shown from pooled triplicate wells; hdaCD4 + T cells 
donor 1 with CLL MNC sample, hdaCD4+ T cells donor 2 with CLL MNC 
sample, CLL MNC sample on L-40 stroma, CLL MNC sample on L-cont 
stroma. 
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These data from the flow-cytometric analyses of proliferation indicated that the apparent 
hdaCD4+ T cell expansion in response to CLL MNC seen by 3H-thymidine (figures 26-29) 
was not a response to CLL and accessory cells per se but rather a response to CLL and 
accessory cells that had been irradiated.  To address this, co-cultures were established to look 
at the CellTrace™ profiles of T cells when they were co-cultured with irradiated CLL MNC 
(figure 37 & 38) and in parallel co-cultures of T cells with irradiated and non-irradiated CLL 
MNC were monitored for their incorporation of 3H-thymidine (figure 39 and 40). 
As seen previously, the use of  CellTrace™ indicated no strong or significant proliferation of 
hdaCD4+ T cells when co-cultured with either irradiated CLL MNC or non-irradiated 
controls.  However, both irradiated and non-irradiated CLL MNC induced the uptake of 3H-
thymidine in co-cultures, although this was seen to a lesser extent in non-irradiated co-
cultures.  Overall these data now indicated that the 3H-thymidine incorporation seen in the 
earlier experiments may not relate solely to proliferation in these co-cultures. 
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Figure 37. Flow cytometry analysis of CellTraceTM fluorescence intensity.  
Prior to culture hdsCD4+ T cells were labelled with CellTrace™ Far Red 
and CLL MNC with CellTrace™ CFSE to monitor cellular proliferation.  
CLL MNC were separated into 2 fractions, one irradiated and the other left 
un-irradiated. Irradiated and non-irradiated fractions of CLL MNC were 
co-cultured with the same hdaCD4+ T cell sample, or a lone as control.  
Cells were each seeded at 2.5x105cells/well in triplicate in the presence of 
IL-21 and harvested at day 5. Proliferation rates were calculated using 
gates R1-R12 as previously described.  
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Figure 38. CellTrace™ analysis of irradiated CLL MNC co-culture with 
hdaCD4+ T cells demonstrated a lack of strong proliferation. 
Prior to culture hdaCD4+ T cells were labelled with CellTrace™ Far Red 
and CLL MNC with CellTrace™ CFSE to monitor cellular proliferation.  
CLL MNC were separated into 2 fractions, one was irradiated and the 
other left un-irradiated.  Irradiated and non-irradiated fractions of the 
CLL MNC samples were co-cultured with the same hdaCD4+ T cell sample, 
or alone as control.  Representative data shown for both dy es of; co-
culture of hdaCD4+ T cells and CLL MNC (irradiated and non-irradiated 
fraction), hdaCD4+ T cells alone and CLL MNC alone (irradiated and non-
irradiated fraction).  Cells were each seeded at 2.5x10 5cells/well in 
triplicate in the presence of IL-21 and harvested at day 5.  Data shown are 
the analysis of events in gates R1-R12 as shown in figure 36. 
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Figure 39. 3H-thymidine incorporation occurred in co-cultures of 
hdaCD4+ T cells with both irradiated and non-irradiated CLL MNC. 
HdaCD4+ T cells were cultured with irradiated CLL MNC (top panel) or 
non-irradiated CLL MNC (bottom panel) each seeded at 2.5x105cells/well 
in triplicate.  Wells were pulsed with 3H-thymidine 24 hours prior to 
harvest and harvested every 24 hours for 7 days.  Average 3H-thymidine 
incorporation is plotted ±S.E.M. for n=9 (top) & n=5 (bottom) samples.  It 
should be noted that different scales are used on each “y” axis which 
reflects the reduced 3H-thymidine incorporation in non-irradiated CLL 
MNC and hdaCD4+ T cell co-cultures.   
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Figure 40. 3H-thymidine incorporation in co-cultures of hdaCD4+ T cells 
and CLL MNC showed significant difference at day 5 and day 7.  
HdaCD4+ T cells were cultured with or without non-irradiated CLL MNC, 
each seeded at 2.5x105cells/well in triplicate.  Wells were pulsed with 3H-
thymidine 24 hours prior to harvest and incorporation was assessed at day 
5 (left) and day 7 (right).  Average 3H-thymidine incorporation is plotted 
±S.E.M. for hdaCD4+ T cells alone vs. co-culture wells.  Data represents 
n=14 & 5 samples at day 5 and 7 respectively.  
 
 
 
 
0
1000
2000
3000
4000
5000
6000
7000
- CLL + CLL
0
1000
2000
3000
4000
5000
6000
7000
- CLL + CLL
3
H
-t
h
y
m
id
in
e
 I
n
co
rp
o
ra
ti
o
n
 (
C
P
M
) 
p=0.0015 p=0.0001 
Day 5 Day 7 
Chapter Four – T cells and CLL cells in vitro 
129 
 
In combination, the collective data confirmed that there was significant uptake of 3H-
thymidine by cells within the co-cultures which appeared to represent a small proportion of 
T cell proliferation which was not limited to cultures with irradiated cells (although 
irradiation of CLL MNC did exacerbate uptake).  Whilst there appeared to be a small 
proportion of T cells which were proliferating by CellTrace™ analysis, these data were 
unsupported by cell cycle analysis, although viability data (figures 31 & 32) confirmed that 
there was a reciprocal pro-survival effect of co-culturing compared to either cell type 
cultured alone indicating cell-cell interaction. 
One explanation for the increase in 3H-thymidine uptake with apparent lack of strong 
proliferation (as seen by CellTrace™ labelling and cell cycle analysis) was that this may 
represent a very tiny percentage of T cells which continually proliferate over the course of 5-
7 days and show an increase the 3H-thymidine counts whilst making only a small impact on 
CellTrace™ readings.  However, the high levels of 3H-thymidine uptake over 7 days does not 
easily reconcile with the small changes in CellTrace™ assays and lack of active cell cycle 
data.  As such, other contributing causes for this apparent disconnect were further 
interrogated.  After consideration of the literature it was noted that 3H-thymidine 
incorporation has also been reported as an indicator of DNA repair (Herman 2002, Cleaver 
2014).  This raised the possibility that a portion of the 3H-thymidine incorporation in co-
cultures could reflect DNA damage repair and that the greater incorporation seen when 
irradiated CLL MNC were used may reflect greater levels of DNA repair by these cells 
(figure 40).  
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4.6 BrdU incorporation of irradiated cultures shows a perinuclear subcellular 
localisation consistent with DNA repair 
To further investigate alternative causes of 3H-Thymidine incorporation by co-cultured cells 
the thymidine analogue bromodeoxyuridine (BrdU) was employed.  This label has the 
advantage that it can be detected immunoflouresently and therefore visualised (Calkins & 
Reddy 2011; Lentz et al. 2010; Campana et al. 1988).  Co-cultures of hdaCD4+ T cells and 
irradiated CLL MNC were pulsed with BrdU containing media in triplicate and harvested at 
days 3, 5 and 7.  Cytospins were created from pooled wells and were subsequently 
immunofluorescently stained for the incorporation of BrdU and observed using confocal 
microscopy.  The main objectives of these experiments were (i) to determine whether the 
incorporation of 3H-thymidine as seen above could be recapitulated by a thymidine analogue 
and (ii) if so, whether the incorporation was localised to a specific cellular compartment 
which could aid in elucidating the mechanism for such uptake. 
Representative data from these experiments is shown (figure 41).  Firstly, these data support 
previous experiments by confirming that uptake of a thymidine analogue occurs in co-
cultures even when using BrdU in place of 3H-thymidine.  Secondly, these data also support 
the theory that DNA repair may be occurring in these co-cultures, as uptake appears to 
localise to a specific subcellular region. 
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Figure 41. Subcellular localisation of BrdU incorporation differs 
between actively proliferating cells and those in co -culture conditions. 
HdaCD4+ T cells were cultured with irradiated CLL MNC each seeded at 
2.5x105cells/well in triplicate.  As a control for proliferating cells, CLL 
MNC (non-irradiated) were cultured on L-40 stroma with IL-21.  Wells 
were pulsed with BrdU at day 0 and harvested at day 3 (CLL L-40) & day 7 
(co-culture). Cytospins from pooled triplicate wells were 
immunofluorescently stained for BrdU incorporation.  Representative 
images (x40 objective) are shown.  Arrow highlights potential perinuclear 
staining, samples labelled with culture condition and [day of culture] . 
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As expected CLL MNC cultured on L-40 stroma in the presence of IL-21 showed strong 
nuclear staining in a sub-population of cells that was consistent with some cells being in S-
phase during the period of pulsing with BrdU.  However, the distribution of BrdU staining 
and level of staining observed within the co-culture was strikingly different.  BrdU+ co-
cultured cells showed a staining pattern reminiscent of a perinuclear rather than intra-
nuclear distribution.  This distribution was visualised dependent upon the focal plane when 
observing the samples and examples of these suspected perinuclear ring structures can be 
seen in figure 41, highlighted by the white arrow.   
Perinuclear location of incorporated BrdU in this preliminary work is consistent with DNA 
repair since it has been reported that damaged DNA is shuttled to the pores in the nuclear 
membrane to allow access to necessary scaffold and repair proteins found in the perinuclear 
region (Nagai et al. 2008).  For confirmation of this suspected perinuclear subcellular 
localisation, future work would look to repeat this experiment in combination with the 
presence of a nuclear stain such as DAPI or Hoescht 33343. 
Attempts were made to combine staining for BrdU with B cell and T cell markers to 
determine whether incorporation was restricted to either CLL MNC or hdaCD4+ T cells.  
However the processing required to render incorporated BrdU accessible for staining 
destroyed the antigenicity of both B and T cell markers.   
Despite these limitations, these new observations in combination with earlier data would be 
consistent with the hypothesis that co-culture of CLL MNC with hdaCD4+ T cells can induce 
T cell-driven CLL MNC DNA repair.  However, it is not possible to rule out a reciprocal 
induction of DNA repair in T cells by co-culture with CLL MNC.  Mutual protection in this 
way could underlie the common improvements in sustained viability in vitro when CLL 
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MNC and hdaCD4+ T cells were co-cultured.  It should also be noted that proliferation of a 
small proportion of the T cell population in these co-cultures may also be occurring and 
account for the 3H-thymidine incorporation observed. 
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4.7 Discussion 
Overall the data presented in this chapter have produced several significant findings which 
will impact future interpretations of data and has given a new insight in to the role that T 
cells may play in the CLL LN. 
Firstly, this work has shown that monitoring 3H-thymidine incorporation as a measure of 
proliferation should always be performed in conjunction with other assays for confirmation.   
Although co-culture of CLL MNC with hdaCD4+ T cells induced the incorporation of 3H-
thymidine, these co-cultures showed only a small amount of proliferation by CellTrace™ 
analysis and this was not confirmed by cell cycle profile analysis.  Further investigations 
using BrdU as an alternative thymidine analogue indicated that a proportion of this 
incorporation may be due to the activation of a DNA repair response, although it should be 
noted that these data were early preliminary findings and would need confirmation in future 
work.  Nevertheless, the response is specific to co-culture wells and is seen to a higher level 
where CLL MNC have been irradiated prior to culture.  These data may also be consistent 
with the presence of a small population of actively proliferating T cells within the co-
cultures, at a level too low to be clearly observed in cell cycle analysis and only seen in small 
numbers when observing the CellTrace™ data. 
Furthermore these data have indicated that non-CLL-non-T cells have an impact on this 3H-
thymidine uptake response either through direct or indirect means.  These data support the 
understanding that multiple cell types within the CLL LN are likely to contribute to CLL 
survival and disease progression.    
An alternative explanation for the suspected perinuclear distribution of BrdU incorporation 
in co-cultures is the induction of mitochondrial replication which can also be focused 
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perinuclearly (Calkins & Reddy 2011; Lentz et al. 2010).  However mitochondrial replication 
also localises to other additional subcellular areas which are not observed in these 
experiments (Calkins & Reddy 2011).  Future experiments should seek to confirm and 
further clarify the subcellular distribution of BrdU incorporation in co-cultures.   
Subsequent work within this project concentrated upon the interaction of CLL cells with 
other cell types in the LN microenvironment, focusing on monocyte-derived cells which 
have been previously indicated as a significant contributor to disease (as discussed in 
Chapter 1.5.3). 
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5 MACROPHAGES & NURSE-LIKE 
CELLS IN THE CLL LN 
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5.1 Introduction 
Data shown here in combination with findings from other groups highlight the significant 
role that non-T cells have upon CLL cells.  In recent studies the supportive role of Nurse-like 
cells (NLC) in the LN has been extensively investigated in-vitro using PB as the source 
(Burger et al. 2000; Ysebaert & Fournié 2011; Tsukada et al. 2002).  As discussed in Chapter 
1.4.3, the presence of these cell types within the LN has recently been suggested however 
little work to confirm this has been performed.  As such this project sought to investigate the 
presence of macrophages and NLC within the CLL LN, primarily to confirm their presence 
in the node and further to consider this presence in the context of stage of disease. 
In addition, the balance of CLL cells with T cells and NLC in the CLL LN were considered in 
concert and collated data indicated a potential new method for categorising CLL patients 
based upon the proportions of these three cell types within the LN.  
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5.2 Nurse-like Cells have a variable presence in CLL LN unrelated to disease 
stage 
As described in Chapter 1.4.3, NLC are cells derived from the monocyte lineage and gene 
expression profiling (GEP) experiments identified close similarities between NLC and the 
immunosuppressive macrophage subtype M2 (Ysebaert & Fournié 2011).  NLC have been 
described as the tumour associated macrophage (TAM) of CLL (Ysebaert & Fournié 2011; 
Filip, Ciseł, Koczkodaj, et al. 2013; Lewis & Pollard 2006) and many in vitro studies have 
shown improved survival and drug resistance of CLL cells during their co-culture with 
autologous NLC (Nishio et al. 2005; Filip, Ciseł & Wasik-Szczepanek 2013; Burger et al. 2000; 
Tsukada et al. 2002). 
Despite these relatively extensive investigations into the role of NLC in vitro, little has been 
shown regarding the presence of NLC in the LN microenvironment and as such this 
distinctive cell type has yet to be considered in context.  In particular it has yet to be 
definitively confirmed that NLC are a significant component of the CLL LN and not a by-
product of the long term ex vivo culture of CLL PB. 
CLL LN tissue sections were stained for the presence of NLC utilising the surface expression 
of CD163.  It should be noted that CD163 is also expressed by the M2 macrophage and as 
such future work would look to determine an independent marker of these cells for 
confirmation.  The presence of CD163+ cells was common across most CLL LN tissues but the 
total numbers varied greatly and in this cohort of samples did not associate with stage of 
disease (figure 42).  It should be noted that sample P3 had no apparent CD163+ in either Z1 
or Z2 areas of the tissue and the cause of this is unclear.  This striking absence may be 
important as CD163+ were seen in both healthy and disease tissues and lack of these cells 
may represent a significant change in the biology of this sample.   
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Figure 42. Average CD163+ cell presence is highly variable and does not 
correlate to disease stage. 
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for the expression of CD163.  Three 
areas from each tissue were imaged (with the exception of sample P3, 
which had 3 areas images from each of Z1 and Z2) and these images were 
quantitatively analysed for CD68+ positivity using Fiji Image J analysis 
software.  Numbers of positive cells were averaged across the three images 
collected for each sample and mean data is plotted ±S.E.M.  Samples are 
labelled with [stage of disease] along the x-axis. 
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Figure 43 shows representative images of stage A and C disease tissues stained for the 
presence of CD163+ cells as well as healthy spleen tissue for comparison.  CD163+ cells were 
not isolated to disease tissue alone but were seen in significant numbers in healthy spleen 
tissue.  Despite the presence of these cells in both healthy and disease tissues, there were 
clear differences in their distribution within spleen tissue v.s. CLL LN tissues (figures 43 and 
44) suggesting that despite a common cell surface marker, the cell types within healthy tissue 
differ in phenotype to those in the CLL LN.  In healthy tissue, the CD163+ cell population 
appear to be adjacent to PAX5+ cells, whilst in CLL LN tissue, when present, CD163+ cells 
appear dispersed within the PAX5+ cell population (figure 44).  This would support the 
current belief that whilst CD163+ in the spleen may relate to normal M2 macrophages, 
CD163+ in the CLL LN relates to NLC presence (figure 45).  Future work is needed to address 
this possibility, although to date an independent marker for NLC has yet to be identified and 
so an alternative approach such as laser capture dissection and GEP of cells from these 
tissues may be better employed to confirm this theory. 
Furthermore, despite close localisation of CD163+ cells to Ki-67+PAX5+ cells (figures 44 and 
45) no correlation was seen between proliferative activity and CD163+ presence in these 
tissues.  
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Figure 43. CD163+ cells may be present in both early and late stage CLL 
cases and appear monocytic based on their morphology.  
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD163 (green).  Representative images (x40 objective) are shown for 
stage A (n=1) and stage C (n=1) patient samples as well as healthy spleen 
tissue (n=1).  The lower right image is a larger, cropped version of the  
upper right image to show morphology in greater detail. An example of 
false positive staining from a red blood cell is highlighted (white arrow).  
Samples labelled with patient code and [stage of disease].  
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Figure 44A. The presence of CD163+ cells varies across CLL tissues irrespective 
of disease stage & their distribution is markedly different in healthy spleen.  
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD163 (green) PAX5 (red) and Ki-67 (blue).  Representative images (x40 
objective) are shown for stage A patient samples (n=4).  Samples labelled 
with patient code and [stage of disease].  Further images for later stage 
disease and healthy spleen tissue shown below.  
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Figure 44B. The presence of CD163+ cells varies across CLL tissues irrespective 
of disease stage & their distribution is markedly different in healthy spleen.  
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD163 (green) PAX5 (red) and Ki-67 (blue).  Continued from figure 44A; 
Representative images (x40 objective) are shown for immunofluorescent 
staining of stage B (n=1) & C (n=2) patient samples and healthy spleen 
tissue (n=1).  Samples labelled with patient code and [stage of disease].  
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Figure 45.  Differences in the distribution of CD163 + cells in CLL LN (at 
all stages of disease) compared to healthy spleen suggest an alternative 
phenotype in disease which may represent NLC.  
CLL LN and healthy spleen tissue sections were stained for the expr ession 
of CD163 (green) PAX5 (red) and Ki-67 (blue).  Representative images (x40 
objective) are shown for stage A (n=1) stage B (n=1) and stage C (n=1) 
patient samples and healthy spleen tissue (n=1).  Samples labelled with 
patient code and [stage of disease]. 
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5.3 Macrophage presence diminishes correlated to stage of disease with no 
apparent relative increase in NLC 
Macrophages have been reported to be present within the CLL LN (Bürkle & Niedermeier 
2007; Maffei et al. 2013) and their presence in these tissue samples was investigated by 
targeting the expression of CD68.  The total number of CD68+ cells in these tissues varied 
(figure 46), and their distribution in CLL LN was different to that seen in healthy spleen 
(figure 47A & B).  Overall, the data indicated a general reduction in the frequency of 
macrophages per field of observation in CLL LN correlated to the advancement of disease 
(figure 48).  Interestingly, as shown in chapter 5.2, this relative decrease in CD68+ 
macrophages did not correlate to changes in CD163+ cell presence in these tissues, despite 
previous reports that NLC are also CD68+.  These data may suggest that CD68 expression by 
NLC alters as disease advances but this is as yet inconclusive.  Confirmation of NLC 
expression of CD68 across different disease stages requires further investigation, including 
dual staining of these tissues with CD68 and CD163. 
Despite these contrasting findings concerning NLC CD68 positivity, the general reduction in 
CD68+ cells (figure 48) does support the current understanding of growing 
immunosuppression within the niche as disease progresses, as lower “healthy” CD68+ 
macrophages would provide less opportunity for functional immune responses against CLL 
cells. 
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Figure 46. The frequency of CD68+ cells in CLL LN tissue varies between 
samples and is typically lower than healthy spleen tissue.  
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for the expression of CD68 +.  Three 
areas from each tissue were imaged (with the exception of sample P3, 
which had 3 areas images from each of Z1 and Z2) and these images were 
quantitatively analysed for CD68 positivity using Fiji Image J analysis 
software.  Numbers of positive cells were averaged across the three images 
collected for each sample and mean data is plotted ±S.E.M.  Samples are 
labelled with [stage of disease] along the x-axis. 
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Figure 47A.  Frequency of CD68+ cells varied across CLL LN samples and 
their distribution differs markedly from that seen in healthy spleen 
tissue. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of Ki-67 (green) PAX5 (red) and CD68 (blue).  Representative images (x40 
objective) are shown for stage A patient samples (n=2).  Samples labelled 
with patient code and [stage of disease] .  Further images for later stage 
disease and healthy spleen tissue shown below.  
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Figure 47B.  Frequency of CD68+ cells varied across CLL LN samples and 
their distribution differs markedly from that seen in healthy spleen 
tissue. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of Ki-67 (green) PAX5 (red) and CD68 (blue).  Continued from figure 47A; 
Representative images (x40 objective) are shown for immunofluorescent 
staining of a stage C (n=1) patient sample and healthy spleen tissue (n=1).  
Samples labelled with patient code and [stage of disease].  
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Figure 48.  Comparison of early and late stage CLL tissue shows a 
decrease in CD68+ cells as disease progresses.  
Sections of seven CLL LN tissue samples were immunofluorescently 
stained for expression of CD68+.  Three areas from each tissue or zone 
were imaged and quantitatively analysed for CD68 + positivity using Fiji 
Image J analysis software.  Numbers of positive cells were averaged across 
the three images and mean data collected for early (stage A (n=4)) and late 
(stage B & C (n=3)) samples to compare the presence of CD68 + cells.  
Average data are plotted ± S.E.M. and differences were statistically 
significant (students t-test). 
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5.4 Nicotinamide phosphoribosyltransferase (NAMPT) expression decreases 
suggesting a reduced recruitment of M2 cells in later stage disease 
As discussed in Chapter 1.4.7, NAMPT is an enzyme and signalling molecule whose 
expression has been linked to the polarisation of macrophages to the M2 subtype in CLL, 
other diseases and in healthy tissues (Audrito et al. 2015).  NAMPT has also been implicated 
as having a role in the recruitment of these cells to specific tissues.  Whilst the levels of 
NAMPT have been studied in PB CLL samples and in vitro culture, little has been studied in 
the LN microenvironment.  This project investigated the expression of NAMPT alone and in 
the context of PAX5 expression in these tissues.  Representative images are shown of seven 
CLL LN tissue sections stained for the presence of NAMPT and PAX5 (figure 49A & B).  
Whilst NAMPT+ cells often appear adjacent to PAX5+ cells there is little to no cellular co-
localisation indicating that CLL cells are not directly expressing this recruitment signal nor 
instructing the polarisation of macrophages to the M2 subtype.  This supports previous 
demonstrations by other groups that NAMPT expression co-localises with CD163 
expression, suggesting NAMPT is a monocyte derived signal and that recruited M2 or NLC 
present in the tissues are the source.  In light of the data presented here, this expression by 
NLC/M2 cells in the LN may be induced by their close proximity to CLL cells.   
These data showed variable expression of NAMPT across individual tissues (figure 50) and 
no direct correlation was seen between NAMPT+ cells and either CD163+ or CD68+ cells 
within in each tissue.  Nevertheless, average expression of NAMPT in early vs. late stage 
disease showed a reduction in expression as disease progresses (figure 51), reflecting the 
trend seen in CD68+ cell presence.  These data suggest that any M2 or NLC recruitment to 
the LN during later stage disease is at least partially NAMPT-independent, or that following 
their recruitment, NAMPT expression is switched off.   Future work would look to stain 
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tissue samples with PAX5, NAMPT and CD163 markers simultaneously, to further clarify 
the cell types which may be expressing NAMPT in the CLL LN. This was not possible within 
the current project due to limitations on the combination of available NAMPT and CD163 
primary antibodies (both were mouse monoclonal antibodies). 
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Figure 49A. NAMPT positivity in CLL is variable and localises adjacent 
to PAX5 staining indicating non-CLL cell expression in the LN. 
CLL LN and healthy spleen tissue sections were stained for the expression 
of NAMPT (green) and PAX5 (red).  Representative images (x40 objective) 
are shown for stage A patient samples (n=4).  Samples labelled with 
patient code and [stage of disease].  Further images for later stage disease  
and healthy spleen tissue shown below.  
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Figure 49B. NAMPT positivity in CLL is variable and localises adjacent 
to PAX5 staining indicating non-CLL cell expression in the LN. 
CLL LN and healthy spleen tissue sections were stained for the expr ession 
of NAMPT (green) and PAX5 (red).  Continued from figure 49A; 
Representative images (x40 objective) are shown for immunofluorescent 
staining of stage B (n=1) & C (n=2) patient samples and healthy spleen 
tissue (n=1).  Samples labelled with patient code and [stage of disease].  
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Figure 50. Expression of NAMPT is variable between CLL LN tissue 
samples. 
Sections of seven CLL LN tissue samples and one healthy spleen sample 
were immunofluorescently stained for the expression of NAMPT.  Three 
areas from each tissue were imaged (with the exception of sample P3, 
which had 3 areas images from each of Z1 and Z2) and these images were 
quantitatively analysed for NAMPT positivity using Fiji Image J analysis 
software.  Numbers of positive cells were averaged across the three images 
collected for each sample and mean data is plotted ± S.E.M.  Samples are 
labelled with [stage of disease] along the x-axis. 
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Figure 51. The comparative frequency of NAMPT expression in early and 
late stage CLL samples suggests a reduction in expression as disease 
progresses. 
Sections of seven CLL LN tissue samples were immunofluorescently 
stained for expression of NAMPT.  Three areas from each tissue or zone 
were imaged and quantitatively analysed for NAMPT positivity using Fiji  
Image J analysis software.  Numbers of positive cells were averaged across 
the three images and mean data collected for early (stage A (n=4)) and late 
(stage B & C (n=3)) samples to compare the presence of NAMPT + cells.  
Average data are plotted ± S.E.M. 
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5.5 The balance of T cells and NLC in the CLL LN varies between patient 
samples and may reflect different subtypes of CLL 
The interaction of CLL cells with T cells and NLC have been the focus of many studies 
within the CLL field.  Whilst these cell types have been considered in isolation, the study of 
all three cell types in combination was deemed important to visualise potential interactions 
in the niche.  Immunofluorescent staining of CLL LN and normal spleen for the presence of 
CD163, CD3 and PAX5 allowed consideration of the spatial distribution of these cell types 
(figure 52A & B) and quantitative analysis allowed insight as to whether proportions of these 
cell types correlated to stage of disease. 
The CLL LN samples could be subdivided into samples with low, medium or high 
frequencies of CD163+ cells, deemed NLC for this analysis.  Based upon these groupings the 
proportions of all three cell types showed distinct differences. 
Whilst “medium” NLC-containing LN had an average ratio of 35 CLL cells and 7 T cells for 
each NLC, “high” NLC–containing LN had an average ratio of 4 CLL cells and 2 T cells for 
each NLC.  These represent comparatively different cellular balances within this important 
microenvironment.  If these differences are representative of the general patient population, 
this would allow the construction of more representative in vitro models of CLL and aid in 
the development of new targeted therapies. 
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Figure 52A. Variable proportions and distribution of T cells & NLC in CLL LN 
tissue may highlight differences that could be exploited therapeutically.  
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD163 (green) PAX5 (red) and CD3 (blue).  Representative images (x10 
and x40 objective (left and right respectively)) are shown for stage A 
patient samples (n=4).  Samples labelled with patient code and [stage of 
disease], further images for later stage disease and healthy spleen tissue 
shown below. 
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Figure 52B. Variable proportions and distribution of T cells & NLC in CLL LN 
tissue may highlight differences that could be exploited therapeutically.  
CLL LN and healthy spleen tissue sections were stained for the expression 
of CD163 (green) PAX5 (red) and CD3 (blue).  Continued from figure 52A; 
Representative images (x10 and x40 objective (left and right respectively)) 
are shown for stage B (n=1) & C (n=2) patient samples and healthy spleen 
tissue (n=1).  Samples labelled with patient code and [stage of dise ase]. 
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5.6 Discussion 
These data have supported the concept that NLC are present within the CLL LN 
microenvironments although CD163+ appears highly variable, unrelated to disease stage and 
unconnected to the reduced presence of CD68+ cells in these nodes.  Whilst NLC have been 
previously compared to the immunosuppressive M2 phenotype and share a common 
extracellular marker, the data collected also fails to show a connection between CD163 and 
NAMPT expression in the tissues.  These data do serve to highlight the complexity of the 
involvement of monocyte/macrophage subtypes within the CLL LN and highlights that 
teasing apart this component of the niche will require further in-depth interrogation of 
tissues with more specific panels of markers. 
Furthermore, the data collected from immunofluorescent staining within this project have 
also highlighted the close spatial relationship of T cells and NLC (CD163+ cells) to CLL cells 
in vivo.   Analysis of the ratios of these supportive cell types have revealed that consideration 
should be given to their proportions within individual patient samples as this may reflect 
different subtypes of disease.  These data warrant future investigation to determine their 
significance. 
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6.1 Discussion 
This study sought to investigate the cellular contents and interactions within the CLL LN, 
through a combination of in vitro co-cultures and ex vivo interrogations of FFPE CLL LN 
tissues.  Ultimately, this project aimed to inform a real-world view of this complex 
microenvironment and highlight the potential benefits of harnessing archived tissues to 
better understand this important niche.  
The CLL LN was investigated for its proliferative signature using Ki-67 expression and 
comparative H&E staining.  The Ki-67 data indicated a lack of the traditionally envisaged 
CLL proliferation centres in all but one CLL sample, a finding contrary to most current 
literature discussions (Ciccone et al. 2012; Soma et al. 2006; Ponzoni et al. 2011).  Reports of 
proliferation centres within CLL LN tissue discuss distinct “pale” areas of tissue (H&E 
staining) containing a concentration of Ki-67+ cells (Schmid & Isaacson 1994; Bonato et al. 
1998).  However, when this study considered the Ki-67 expression of CLL LN tissues, in 
combination with many other markers across serial sections of samples, distinct centres of 
proliferation were absent in all but sample P3 - despite the appearance of these structures in 
the H&E staining data.  These data suggest that proliferation centre may be a misnomer, 
where these pale areas seen in H&E staining relate more to the interaction of CLL cells with 
different supportive cell types rather than areas of intense proliferation.  Indeed this work is 
supported by observations of such architecture by other groups (Vandewoestyne et al. 2011) 
and may indicate that the use of the alternative name for these areas – pseudofollicles – 
would be more appropriate.  This concept requires further investigation. 
Initial studies also revealed that as disease progresses, tumour cells appear to lose some of 
the normal features of B cells, as evidenced by the decreased expression of the important 
pan-B cell marker PAX5.  Tissue sections were analysed for their mean fluorescence intensity 
Chapter Six – General Discussion 
162 
 
of PAX5 signal (instead of numbers of cells expressing PAX5) due to a limitation in the 
sensitivity of the analysis software in distinguishing adjacent PAX5+ cells from one another.  
As such, the observation that PAX5 expression decreases as stage of disease progresses will 
need further investigation to determine whether it represents a reduction in the total number 
of cells expressing PAX5, a reduction in the amount of PAX5 expression within individual 
cells or a combination of these scenarios.  Regardless of the mechanism of PAX5+ reduction, 
this is a key finding.  PAX5 is an important transcription factor which directs the 
development of CLP along the B cell lineage, expressed from the pre-B cell stage of 
development until B cell differentiation into plasma cells (Cobaleda et al. 2007).  Mutations in 
this transcription factor have been indicated to predispose individuals to B cell Acute 
Lymphoblastic Leukaemia (B-ALL) (Hyde & Liu 2013) and it has been recently shown that 
PAX5- Mantle Cell Lymphoma cells have higher levels of proliferation, are more invasive in 
vivo and display a higher resistance to current therapy (Teo et al. 2015), confirming a role for 
this transcription factor in tumour progression.  Even more indicative of a change in biology 
is the reduction seen in Ki67+ tumour cells; whilst the average drop in PAX5 expression in 
stage B&C samples compared to stage A samples was ~33%, the drop in Ki-67+PAX5+ cells 
between these stages was ~66%, indicating that proliferative tumour cells are more likely to 
have reduced PAX5 expression.  When considered in this context, the reduction in PAX5 
expression seems telling of a gradual underlying change in the tumour cell biology of CLL.  
This hypothesis could only be confirmed by the staining of serial tissue samples from the 
same patients to follow disease progression over time. 
Proliferative Ki67+ CLL cells were shown to be often adjacent to T cells, which were 
dispersed throughout the tissues.  Whilst the presence of T cells, even when considering 
subtypes, appeared unrelated to stage of disease it was apparent that the structural layout of 
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the CLL LN varied from sample to sample and this structural degradation may be linked to 
disease stage. 
The balance of apoptosis and proliferation was interrogated using Ki-67 and cleaved caspase 
3 expression in each of the samples, demonstrating that even from early stage disease the 
balance between these fundamental cellular processes are skewed.  This finding fits well 
with the current understanding that the CLL LN is a pro-survival environment for CLL cells 
and in combination with data from other groups indicates that the relatively significant 
amount of CLL cell death per day (estimated up to ~1x1012 CLL cells die per day (Messmer et 
al. 2005; Chiorazzi 2007)) predominantly occurs in the periphery.  This further supports the 
notion that prolonged exclusion from the supportive LN microenvironment alone may well 
be sufficient to induce cell death in CLL cells and is supported by the efficacy seen of the 
BCR inhibitor therapies which exclude cells from the node.  It was intriguing to note the 
variability between different patient samples in their ratios of proliferation to apoptosis; for 
example both samples P2 and P4 were classed as stage A CLL disease but had a distinctly 
higher balance of proliferation to apoptosis compared to other stage A samples in this study.  
It would be interesting to determine whether this reflected the type of disease these patient 
samples represent (e.g. early v.s. late stage A or perhaps M-CLL v.s. U-CLL samples) and 
future work will look to determine whether these samples do differ in their biology.  Future 
work will also look to investigate other markers of apoptosis which could be used to confirm 
these intriguing preliminary findings. 
Based on these initial data and the visually intriguing intimacy of T cells to the proliferative 
components of the tumour clone in CLL, an in vitro study was initiated to look into T cell-
CLL cell interactions.  In healthy individuals, CD4+ Th cell activation, through engagement of 
the MHC II on B cells induces proliferation of the T cell, up regulation of CD40L on its cell 
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surface and subsequent reciprocal activation of the B cell; ultimately leading to both cell 
types proliferating (Klaus et al. 1999). 
Here a co-culture assay was used to investigate the interactions between T cells and CLL 
cells.  The experiments used allogeneic T cells, isolated from healthy volunteer donors 
(hdaCD4+ T cells).  As CLL cells have been shown to dysregulate the T cell compartment in 
CLL, using autologous T cells in these cultures would have required artificial stimulation 
prior to co-culture, for example the addition of anti-CD3 and anti-CD28 activating 
antibodies.  This stimulation could have potentially masked any observation of cognate 
CLL:T cell activation.  Unlike autologous T cell interactions, allogeneic T cells co-cultured 
with CLL cells should induce a non-self-immune response.  As inducers of a non-self-
immune response it was predicted that interactions of allogeneic T cells and CLL cells would 
drive the up-regulation of CD40L expression by CD4+ Th cells and induce the release of 
activating cytokines, such as IL-2 and IL-4 (Saudemont & Madrigal 2014; Ramsay et al. 2008).  
The presence of such signals would reciprocally activate the CLL cells to proliferate.  In this 
way the use of allogeneic T cells would promote CLL cell proliferation and survival, via 
many of the cognate and paracrine signals hypothesised to be important during CLL:T cell 
interactions in the malignant LN.  However, despite this expectation, the data presented here 
indicates that the majority of hdaCD4+ T cells do not proliferate in response to co-culture 
with CLL samples and nor do they induce proliferation of CLL cells. 
The lack of CLL cell proliferation in this co-culture is informative, indicating that there were 
insufficient stimulatory signals present to induce CLL proliferation.  As such, the co-culture 
does not recapitulate the proliferative qualities of the LN microenvironment (as can be seen 
from data presented in Chapter 4).  Despite a lack of CLL cell proliferation, the co-cultures 
did replicate the protective aspects of the LN microenvironment.  Co-cultures cells had 
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higher viability compared to each cell type cultured alone indicating the induction of a pro-
survival signature for both cell types. 
As discussed in Chapter 4.7 the staining of BrdU incorporation seen from cells in co-culture 
wells appeared strikingly different in its localisation and quantity when compared to actively 
proliferating cells.  The distribution of this staining, which appeared reminiscent of 
perinuclear localisation, is unlikely to be a consequence of mitochondrial replication as the 
subcellular localisation of this is understood to be both perinuclear and dispersed within the 
cytoplasm (Calkins & Reddy 2011; Lentz et al. 2010), which was not apparent in these 
images.  If confirmed by future work - by combining this staining with a nuclear stain - this 
would suggest that cells within the co-culture are undergoing DNA repair processes, where 
perinuclear localisation is due to the transport of damaged DNA to nuclear pores for repair 
(Lee 2001, Nagai 2008).  Confirmation of these data is required and should also include an 
assay that can determine levels of DNA damage and repair, such as the comet assay (Collins 
2004). 
The data also show that the irradiation of CLL samples prior to their co-culture produced a 
higher incorporation of 3H-thymidine than non-irradiated samples.  Irradiation has been 
shown to cause DNA damage and cell cycle arrest as part of the cellular stress response 
(Bluwstein et al., 2013).  In light of this, it could be proposed that “additional” DNA damage 
present in the CLL samples caused by irradiation prior to co-culture is reflected in a higher 
amount of DNA repair during culture. 
It has been previously described that CLL samples are capable of DNA repair within 2 hours 
of treatment with DNA damaging agents, although this ability varies greatly between 
samples (Muller 1997) and is at relatively low levels (Barret et al. 1996).  As CLL cells appear 
Chapter Six – General Discussion 
166 
 
predisposed to DNA repair, the data presented here suggest that it is the CLL cells within 
the co-culture, rather than the hdaCD4+ T cells, that are undergoing DNA repair and that 
these high levels of repair are only possible in the presence of T cells.  In addition, it could be 
postulated that the non-CLL MNC fraction (which would include autologous T cells) could 
be responsible for previously reported low-level DNA repair.  As such, future work for this 
study should consider the role of autologous T cells present within the co-culture assay.  
These collective data insinuate that CLL cells initiate DNA repair in the presence of 
allogeneic T cells and that this response may reflect a process that also occurs with 
autologous T cells. 
Overall these findings have considerable implications when considering the CLL LN 
microenvironment.  It is understood that the LN microenvironment can protect CLL cells 
from many front-line therapies but the exact mechanisms are as yet unclear.  If the responses 
seen in this study are confirmed in future work and are similar to the effect that autologous T 
cells have upon CLL cells in the LN microenvironment, this would indicate that T cells in the 
LN assist CLL cells initiating DNA repair following chemotherapy and/or radiation therapy.  
When considered in the context of current front line therapies used to treat CLL this 
information becomes even more intriguing.  The gold standard of therapy in CLL treatment 
for many patients remains the chemoimmunotherapy combination FCR. 
These data would suggest that the way in which patients are treated could be improved to 
minimise the protective effect of the CLL LN and produce more robust remissions.  The use 
of a T cell targeting therapy in combination with current front-line DNA damaging agents 
may help reduce the ability of CLL cells to recover from this treatment.  Alternatively, it 
could be recommended that future combinations of therapies should exclude DNA 
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damaging agents entirely, or include inhibitors of DNA repair in order to minimise the 
induction of support from the CLL LN following treatments. 
Whilst this theory of T cell driven CLL cell DNA repair is intriguing, an alternative 
explanation for the current data can be proposed.  This is that a small population of T cells 
within the co-culture have consistently and exponentially proliferated over the course of 5-7 
days.  In doing so, they account, at least in part, for the large amount of 3H-thymidine 
incorporation seen by the end of the co-culture experiments.  This expanded cell population 
is likely to be of hdaCD4+ T cell origin as it is present within both irradiated and non-
irradiated co-cultures.  Despite the observation of a variable and small presence of 
proliferating T cells via CellTrace™, the lack of detection of this population via cell cycle 
analysis remains discouraging.  However, it should be noted that these co-cultures were 
analysed for cell cycle activity and CellTrace™ analysis at day 5 whilst the peak 
incorporation of 3H-thymidine was seen at day 7 and this may account for the discrepancies 
seen between these forms of analysis.  Future work should look to measure CellTrace™ and 
cell cycle activity every 24 hours for 7 days of co-culture to determine if there are any 
changes in either parameter that can be observed.  This would need careful planning as the 
amount of available primary material to initiate these experiments was a continuing 
limitation within this project.  Nevertheless, if a small population of hdaCD4+ T cells are 
proliferating in these co-cultures, future work should look to determine whether they 
represent a specific subset of T cells.  Based on current data which demonstrated an increase 
in the viability of CLL cells and T cells within these cultures, it could be postulated that these 
cells are unlikely to be Th1 effector cells, which have a role in Fas-mediated cell killing.  
Alternatively, if this population of expanding cells are Th1 cells, their ability to induce CLL 
cell death may have already been perturbed by the presence of CLL cells within the cultures, 
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similar to the reported effects CLL cells have upon autologous T cells as discussed in 
Chapter 1.5.3. 
This work highlights the potential for misinterpretation of 3H-thymidine incorporation, 
which is still routinely used as a marker of proliferation and of DNA damage repair.  This 
study suggests caution in its future use and recommends that it be used as a tool in 
combination with several other markers of cellular proliferation or DNA repair to elucidate 
the true meaning. 
The data also indicated that a proportion of 3H-thymidine incorporation within co-culture 
wells was driven by the presence of accessory cells, from the non-CLL MNC fraction of CLL 
PB.  The additive responses seen by unpurified CLL samples in these co-cultures advocates 
the use of unpurified CLL samples during in vitro culture to better represent the cellular 
presence in the LN.  Additionally these data suggest a significant role for other cell types in 
supporting CLL DNA repair processes and/or the expansion of T cells. 
Finally, it should be noted that these data need to be compared with the co-culture of 
hdaCD4+ T cells and healthy B cell or healthy MNC counterparts to determine if the 
responses seen are truly CLL specific. 
In addition to T cells, macrophages and NLC are of significant interest within the CLL LN 
microenvironment due to studies showing their ability to promote CLL cell survival and 
drug resistance (Burger et al. 2013; Burger et al. 2000).  As mentioned in Chapter 1, NLC are 
thought to derive from the monocyte/macrophage lineage and represent the tumour 
associated macrophage population within CLL (Filip et al. 2013).  These NLC have been 
shown to express CD163 in addition to CD68 in vitro and as such are difficult to distinguish 
from the M2 polarised macrophage population (Giannoni et al. 2014; Tsukada et al. 2002; 
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Burger et al. 2000; Ysebaert & Fournié 2011).  Nevertheless, the role of tumour-associated 
macrophages in solid cancers has been well documented (Lewis & Pollard 2006) and CD163 
is used as a marker of tumour associated macrophages (TAM) in classical Hodgkins 
lymphoma (Harris et al. 2012), with its presence being shown to predict outcome in these 
patients (Klein et al. 2014). 
As the presence of NLC in the CLL LN had not been widely investigated, this project 
examined the presence of CD163+ cells in these tissues to provide a putative insight into NLC 
presence in this niche. 
Whilst initial studies herein confirmed the presence of CD163+ cells in the CLL LN 
microenvironment it also highlighted the large variability of this presence.  Although a 
reduction in both CD68+ cell presence and NAMPT expression correlated to stage of disease 
this did not appear to relate to CD163+ presence. 
Notably, whilst the majority of samples did show some relationship in their expression of 
CD68 and CD163, this was completely absent in two patient samples - P4 & P7 (figures 40 
and 44).  Both P4 (stage A) and P7 (stage C) had relatively high expression of CD163 with a 
lack of heightened CD68+ cell presence.  Overall these data suggest that there may be three 
distinct subsets of monocyte-lineage cells within these samples; CD68+ CD163- (currently 
thought to represent M1 type macrophages), CD68+ CD163+ (currently thought to represent 
M2 polarised macrophages/TAM/NLCs) and CD68- CD163+ cells which are previously 
unreported.  This population of CD68-CD163+ cells may represent a different form of 
monocyte/macrophage cell and requires further characterisation to determine its possible 
role in CLL. 
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Overall, these preliminary data are insufficient to confirm the presence of NLC in the CLL 
LN and further testing with more cell-specific markers is required.  Nevertheless, these data 
do highlight the presence of several distinct macrophage/monocyte cell types present in 
varying levels within the CLL LN that warrant further investigation. 
As seen in previous work, the use of multicolour staining does highlight the cellular 
architecture within the CLL niche which would otherwise go unobserved (Patten et al. 2008; 
Vandewoestyne et al. 2011).  This ability to stain for multiple cell types and markers 
simultaneously in each tissue allows for robust quantification and comparison of the 
proportions of these cell types, leading to a novel insight into this important 
microenvironment. 
Whilst the absolute numbers of these accessory cells in these tissues had no clear link to the 
stage of disease of patients and the number of patient samples in this study were small, the 
data suggested that these samples could be categorised based on CLL cell to accessory cell 
ratios.  Within this cohort there appears to be different types of LN microenvironment; those 
with high CD163+ NLC who typically had low ratios of T cells to NLC and CLL cells and 
those with low CD163+ NLC, which have a much higher comparative presence of T cells 
(representation of this seen in figure 53 below).   
These differences may reflect types of CLL disease which have high or low reliance upon the 
external LN microenvironment and it would be important in future work to correlate the 
proportions of these cell types to disease progression and response to therapy. 
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Figure 53. Representation of the differences between “medium” and 
“high” Nurse-like cell presence in the LN. 
Whilst “medium” samples had an average of thirty -five CLL cells (red) 
and seven T cells (blue) per NLC (orange), “high” samples had an average 
of four CLL cells and two T cells.  These lead to striking differences in the 
cellular architecture in these LN samples.  
 
CLL cell 
T cell 
NLC 
“Medium” NLC presence 
“High” NLC presence 
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This work may prove to be a new method for stratification of patients and help to determine 
the types of therapy which would be most suitable.  A limitation of this study was the lack of 
healthy LN tissue for direct comparison and future work should look to address this.  It 
could be argued that based on the analysis of these samples, patient sample P3 would be best 
utilised as a form of control for the patient cohort in lieu of the availability of healthy LN 
tissue.  This suggestion is based on a combination of the tissue architecture (where there 
appears to be germinal centre structures and T cells zones remaining), the expression levels 
of the different cell markers seen within this study and the patient notes which appear to 
indicate that the disease resolved over time.  However utilising sample P3 in this manner 
would need to be approached with caution, as this could greatly impact the way in which 
the overall sample data were analysed and would likely skew the interpretation of such a 
small study; healthy lymph node tissue would still be the most beneficial as a reliable control 
for these samples.  Future work should also include multicolour immunofluorescent 
interrogation of more CLL patients FFPE LN samples to strengthen the initial findings 
highlighted within this study.  In particular, confirming the presence and role of NLC in 
combination with T cells and CLL cells in the LN is of key importance.   
To confirm the findings from the in vitro studies, future investigation of the relative levels of 
DNA damage in CLL samples pre- and post-co-culture with both hdaCD4+ T cells and 
autologous T cells is needed.  In addition, the impact of chemotherapy on these cultures 
would be important to determine and will be a future aim for the project 
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Buffers and Recipes 
2.2.3 MACS Buffer 
500mL DPBS with the addition of 2mM sterile filtered EDTA and 1% (v/v) FBS. Store at 4oC. 
 
2.5.3 FACS Fix (Flow Cytometry) 
500mL DPBS with addition of 1% (v/v) formaldehyde and 2% (v\v) FBS. Store at 4oC 
 
2.5.4 Cell Cycle Buffer (Flow Cytometry) 
500mL ddH2O with the addition of 30µg PI, 0.1mM NaCl2, 1% (w/v) sodium citrate, 0.1% 
TritonX100. Store at 4oC protected from light. 
 
 
Quantitative Analysis of Immunofluorescent staining 
 
3.3 Use of Fiji Image J for quantitative analysis. 
For analysis of the expression of a particular marker, multicolour immunofluorescent images 
were analysed by using Fiji Image J Open Source Software and custom built macros which 
allowed automation of the analysis stages to ensure consistency across all samples. Each 
stage of analysis briefly described herein. 
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(A) Multicolour images 
were initially split into their 
four separate colour 
channels.  In this example, 
PAX5 staining is in red, 
whilst nuclear staining 
(important for removing 
false positive events) is in 
grey. The green channel (Ki-
67) and blue channel (Cd68) 
would be closed as these 
were not required for this 
analysis. 
(A)  
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The marker of interest (PAX5) was initially analysed.  First, the brightness/contrast levels 
were altered to ensure good definition of stained v.s. non stained cells (B). This was 
calculated through use of the isotype control staining images to ensure false positivity was 
not introduced.  Subsequently, the image was converted using a threshold function to a 
binary image (C), where black = on/yes and white = off/no.  The binary image allowed the 
software to determine the edge of the staining area for each event or cell. 
(B)  
(C)  
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Once in binary form, the Analyse Particles function could be employed, which allowed number of 
events (or particles/cells) to be counted based upon sizing parameters (D).  The size parameters for 
each staining target were determined individually based upon the isotype control staining to ensure 
accuracy.  Small events were excluded (typically 10micron2) to remove any debris or non-cellular 
staining and very large events were typically excluded to prevent large vessels or clumps of cells 
being included in the analysis.  Numbers of events for each analysis were stored and analysed in 
Microsoft Excel. 
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Once the staining of interest was recorded (D), the nuclear staining channel (DAPI) could be 
employed to remove any false-positive staining due to red blood cell autofluorescence.  The 
DAPI channel brightness/contrast settings were adjusted to leave only the extremely bright 
events (autofluorescence) (E) and then the previously analysed marker of interest (for 
example PAX5 staining) (F) was overlayed onto the DAPI channel (G).  The overlay could 
then be reanalysed for positivity and anything which had high positivity in the DAPI 
(E)  
(F)  
(G)  
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channel was excluded from subsequent analysis.  Numbers of events for each analysis were 
stored and analysed in Microsoft Excel. 
Supplementary Data 
4.4 Flow Cytometry analysis of CLL sample CD19 purity 
 
 
 
 
 
 
 
 
 
 
 
Representative images show a single CLL sample tested for purity pre- and post-negative 
selection purification. 
CD19 
C
D
3
 
Unstained control 
Unpurified CLL  Purified CLL 
74.83% 92.61% 
 
